{"id": "article-19222_0", "title": "Cervical Cancer -- Continuing Education Activity", "content": "Cervical cancer, the fourth most common cancer among women worldwide, is caused almost entirely by human papillomavirus (HPV). High-risk types of HPV can lead to cervical intraepithelial lesions which, over time, can progress to cervical cancer. In the United States and other developed countries, most screening and early detection efforts involve HPV testing and Papanicolaou (Pap) smears. HPV testing identifies exposure to both low- and high-risk types of HPV,\u00a0whereas Pap smears identify abnormal cytology.", "contents": "Cervical Cancer -- Continuing Education Activity. Cervical cancer, the fourth most common cancer among women worldwide, is caused almost entirely by human papillomavirus (HPV). High-risk types of HPV can lead to cervical intraepithelial lesions which, over time, can progress to cervical cancer. In the United States and other developed countries, most screening and early detection efforts involve HPV testing and Papanicolaou (Pap) smears. HPV testing identifies exposure to both low- and high-risk types of HPV,\u00a0whereas Pap smears identify abnormal cytology."}
{"id": "article-19222_1", "title": "Cervical Cancer -- Continuing Education Activity", "content": "Cervical cancer is a largely preventable disease. Primary prevention and screening are the most effective modalities for decreasing the healthcare burden and mortality attributable to cervical cancer. Since 2006, HPV vaccination has been available to prevent cervical cancer. Interprofessional team members must educate young female patients\u00a0(ideally, prior to initiating sexual activity) and their families about this highly effective vaccine. This activity details primary prevention strategies, screening guidelines, diagnostic evaluations, current staging, and specific treatment modalities for invasive cervical cancer.", "contents": "Cervical Cancer -- Continuing Education Activity. Cervical cancer is a largely preventable disease. Primary prevention and screening are the most effective modalities for decreasing the healthcare burden and mortality attributable to cervical cancer. Since 2006, HPV vaccination has been available to prevent cervical cancer. Interprofessional team members must educate young female patients\u00a0(ideally, prior to initiating sexual activity) and their families about this highly effective vaccine. This activity details primary prevention strategies, screening guidelines, diagnostic evaluations, current staging, and specific treatment modalities for invasive cervical cancer."}
{"id": "article-19222_2", "title": "Cervical Cancer -- Continuing Education Activity", "content": "Objectives: Identify the risk factors, signs, and symptoms of cervical cancer, including the role of high-risk HPV types in its development. Apply evidence-based treatment modalities for precancerous cervical lesions, and assess the indications, techniques, potential complications, and follow-up care associated with these interventions. Select appropriate treatment modalities for invasive cervical cancer based on patient characteristics, staging, and available options, including surgery, radiation, and chemotherapy. Collaborate with the interprofessional team to increase HPV vaccination initiatives and to ensure coordinated and comprehensive care for patients diagnosed with cervical cancer. Earn FREE continuing education credits (CME/CE) on this topic.", "contents": "Cervical Cancer -- Continuing Education Activity. Objectives: Identify the risk factors, signs, and symptoms of cervical cancer, including the role of high-risk HPV types in its development. Apply evidence-based treatment modalities for precancerous cervical lesions, and assess the indications, techniques, potential complications, and follow-up care associated with these interventions. Select appropriate treatment modalities for invasive cervical cancer based on patient characteristics, staging, and available options, including surgery, radiation, and chemotherapy. Collaborate with the interprofessional team to increase HPV vaccination initiatives and to ensure coordinated and comprehensive care for patients diagnosed with cervical cancer. Earn FREE continuing education credits (CME/CE) on this topic."}
{"id": "article-19222_3", "title": "Cervical Cancer -- Introduction", "content": "Cervical cancer continues to\u00a0rank among the top gynecologic cancers worldwide. According to current data, it is ranked 14th among all cancers and is the 4th most common cancer among women worldwide. [1] Cervical cancer intervention focuses on primary and secondary prevention. [2] Primary prevention and screening\u00a0are the best methods to decrease the burden of cervical cancer and mortality.", "contents": "Cervical Cancer -- Introduction. Cervical cancer continues to\u00a0rank among the top gynecologic cancers worldwide. According to current data, it is ranked 14th among all cancers and is the 4th most common cancer among women worldwide. [1] Cervical cancer intervention focuses on primary and secondary prevention. [2] Primary prevention and screening\u00a0are the best methods to decrease the burden of cervical cancer and mortality."}
{"id": "article-19222_4", "title": "Cervical Cancer -- Introduction", "content": "In the United States and other developed countries, most screening and diagnostic efforts are directed toward the early\u00a0identification of high-risk human papillomavirus\u00a0(HPV) lesions\u00a0through HPV testing and Papanicolaou (Pap) smears. Although HPV testing is not recommended in women younger than 30 years,\u00a0low-risk\u00a0younger women should\u00a0begin screening with Pap tests at age 21 and continue\u00a0until age 65,\u00a0per the United States Preventive Services Task Force (USPSTF) recommendations. Newer recommendations offer 3- to 5-year intervals between screenings based on a patient's prior results and the use of Pap and HPV cotesting. [3] [4]", "contents": "Cervical Cancer -- Introduction. In the United States and other developed countries, most screening and diagnostic efforts are directed toward the early\u00a0identification of high-risk human papillomavirus\u00a0(HPV) lesions\u00a0through HPV testing and Papanicolaou (Pap) smears. Although HPV testing is not recommended in women younger than 30 years,\u00a0low-risk\u00a0younger women should\u00a0begin screening with Pap tests at age 21 and continue\u00a0until age 65,\u00a0per the United States Preventive Services Task Force (USPSTF) recommendations. Newer recommendations offer 3- to 5-year intervals between screenings based on a patient's prior results and the use of Pap and HPV cotesting. [3] [4]"}
{"id": "article-19222_5", "title": "Cervical Cancer -- Introduction", "content": "Like many diseases and cancers, disparities exist in screening, early diagnosis, and timely treatment rates.\u00a0Screening rates are lower in low socioeconomic and low-resource areas with racial, ethnic, and age variations. Studies show women with obesity and chronic disease may have lower cervical and breast cancer screening rates. A study of ethnic minority women in the United\u00a0Kingdom reports several barriers to screening, including lack of awareness, fear, embarrassment, shame, and low perceived risk. [5] Another study reviewing the barriers for Haitian women revealed socioeconomic barriers, language barriers, and a limited understanding of health and disease. [6] In the United States, cervical cancer mortality is disproportionately higher\u00a0in\u00a0black women.", "contents": "Cervical Cancer -- Introduction. Like many diseases and cancers, disparities exist in screening, early diagnosis, and timely treatment rates.\u00a0Screening rates are lower in low socioeconomic and low-resource areas with racial, ethnic, and age variations. Studies show women with obesity and chronic disease may have lower cervical and breast cancer screening rates. A study of ethnic minority women in the United\u00a0Kingdom reports several barriers to screening, including lack of awareness, fear, embarrassment, shame, and low perceived risk. [5] Another study reviewing the barriers for Haitian women revealed socioeconomic barriers, language barriers, and a limited understanding of health and disease. [6] In the United States, cervical cancer mortality is disproportionately higher\u00a0in\u00a0black women."}
{"id": "article-19222_6", "title": "Cervical Cancer -- Introduction", "content": "As cervical cancer is a sexually transmitted infection (STI), it is preventable, and the global incidence can be reduced through targeted education, screening, and intervention. Since 2006, vaccination has been available for the prevention of cervical cancer. Vaccination can improve cancer death rates\u00a0in populations with higher mortality rates and in\u00a0developing countries where resources may not be available for routine screening.", "contents": "Cervical Cancer -- Introduction. As cervical cancer is a sexually transmitted infection (STI), it is preventable, and the global incidence can be reduced through targeted education, screening, and intervention. Since 2006, vaccination has been available for the prevention of cervical cancer. Vaccination can improve cancer death rates\u00a0in populations with higher mortality rates and in\u00a0developing countries where resources may not be available for routine screening."}
{"id": "article-19222_7", "title": "Cervical Cancer -- Etiology", "content": "Current literature reports that HPV is found in most sexually\u00a0active people at some point during their lifetime. There are more than 130 types of known HPV, with 20\u00a0HPV types identified as cancer-related. HPV exposure rates\u00a0are only known in women since men are not screened outside of research\u00a0protocols.\u00a0HPV\u00a0types 16 and 18 are the most common HPV types identified in invasive cervical cancer. Population-based HPV prevalence studies show the greatest prevalence of high-risk HPV occurs in adults younger than\u00a025 years, and cervical cancer deaths peak in middle-aged\u00a0women\u00a0between 40 and 50 years. Studies have shown that HPV-related cervical disease in women younger than 25 years is largely self-limiting. However, those with coinfection of multiple HPV types may be less likely to have spontaneous clearance and, thus, progress to cancer.", "contents": "Cervical Cancer -- Etiology. Current literature reports that HPV is found in most sexually\u00a0active people at some point during their lifetime. There are more than 130 types of known HPV, with 20\u00a0HPV types identified as cancer-related. HPV exposure rates\u00a0are only known in women since men are not screened outside of research\u00a0protocols.\u00a0HPV\u00a0types 16 and 18 are the most common HPV types identified in invasive cervical cancer. Population-based HPV prevalence studies show the greatest prevalence of high-risk HPV occurs in adults younger than\u00a025 years, and cervical cancer deaths peak in middle-aged\u00a0women\u00a0between 40 and 50 years. Studies have shown that HPV-related cervical disease in women younger than 25 years is largely self-limiting. However, those with coinfection of multiple HPV types may be less likely to have spontaneous clearance and, thus, progress to cancer."}
{"id": "article-19222_8", "title": "Cervical Cancer -- Etiology", "content": "HPV is transmitted by skin-to-skin contact, including during sexual intercourse, hand-to-genital contact, and oral sex. Risk factors for HPV and cervical cancer include young age at sexual initiation, multiple sexual partners, high parity, smoking, herpes simplex, HIV, coinfection with other genital infections, and oral contraceptive use. [7] [8]", "contents": "Cervical Cancer -- Etiology. HPV is transmitted by skin-to-skin contact, including during sexual intercourse, hand-to-genital contact, and oral sex. Risk factors for HPV and cervical cancer include young age at sexual initiation, multiple sexual partners, high parity, smoking, herpes simplex, HIV, coinfection with other genital infections, and oral contraceptive use. [7] [8]"}
{"id": "article-19222_9", "title": "Cervical Cancer -- Epidemiology", "content": "Persistent HPV infection causes more than 99% of all cervical cancers. Every year, there are more than 500,000 new cases of cervical cancer and approximately 250,000 deaths due to cervical cancer worldwide. Eighty percent of cases occur in developing countries. [9] In the United States, about 4000 women die yearly from cervical cancer. Blacks, Hispanics, and women in low-resource areas have more disparity\u00a0in evidenced-based care and a\u00a0significantly\u00a0higher mortality rate. [10] [11] Mortality is\u00a0higher among women not screened in the past 5 years and those without consistent follow-up after identifying a precancerous cervical lesion. Trends show that women with the highest-mortality risk may be less likely to receive HPV vaccination.", "contents": "Cervical Cancer -- Epidemiology. Persistent HPV infection causes more than 99% of all cervical cancers. Every year, there are more than 500,000 new cases of cervical cancer and approximately 250,000 deaths due to cervical cancer worldwide. Eighty percent of cases occur in developing countries. [9] In the United States, about 4000 women die yearly from cervical cancer. Blacks, Hispanics, and women in low-resource areas have more disparity\u00a0in evidenced-based care and a\u00a0significantly\u00a0higher mortality rate. [10] [11] Mortality is\u00a0higher among women not screened in the past 5 years and those without consistent follow-up after identifying a precancerous cervical lesion. Trends show that women with the highest-mortality risk may be less likely to receive HPV vaccination."}
{"id": "article-19222_10", "title": "Cervical Cancer -- Pathophysiology", "content": "More than 75% of cervical cancer cases are due to high-risk HPV types 16 and 18. [12] Other HPV types also can cause malignancy. Some low-risk HPV types, specifically types 6 and 11, cause\u00a0condylomata acuminate, commonly referred to as anogenital warts. Although there are more than half a million cases of HPV identified annually, most are low-grade infections and will spontaneously resolve within\u00a02 years. The progression of high-grade lesions and cancer is seen in the presence of other carcinogenic risk factors, as previously described.", "contents": "Cervical Cancer -- Pathophysiology. More than 75% of cervical cancer cases are due to high-risk HPV types 16 and 18. [12] Other HPV types also can cause malignancy. Some low-risk HPV types, specifically types 6 and 11, cause\u00a0condylomata acuminate, commonly referred to as anogenital warts. Although there are more than half a million cases of HPV identified annually, most are low-grade infections and will spontaneously resolve within\u00a02 years. The progression of high-grade lesions and cancer is seen in the presence of other carcinogenic risk factors, as previously described."}
{"id": "article-19222_11", "title": "Cervical Cancer -- Pathophysiology", "content": "Within HPV DNA, the\u00a0oncoproteins E6 and E7 interfere with the critical host cell cycle; specifically, E6 interferes with\u00a0suppressive tumor protein p53,\u00a0whereas E7 interferes with retinoblastoma protein (pRB). Additionally, the\u00a0E5 protein\u00a0may play a role in immune evasion. These are significant factors in HPV-related neoplasia, including primary vagina cancer. [13] Oxidative stress and microRNAs are believed to play a role in cervical carcinogenesis. Future research to elucidate the proposed interplay is needed. [12] [14]", "contents": "Cervical Cancer -- Pathophysiology. Within HPV DNA, the\u00a0oncoproteins E6 and E7 interfere with the critical host cell cycle; specifically, E6 interferes with\u00a0suppressive tumor protein p53,\u00a0whereas E7 interferes with retinoblastoma protein (pRB). Additionally, the\u00a0E5 protein\u00a0may play a role in immune evasion. These are significant factors in HPV-related neoplasia, including primary vagina cancer. [13] Oxidative stress and microRNAs are believed to play a role in cervical carcinogenesis. Future research to elucidate the proposed interplay is needed. [12] [14]"}
{"id": "article-19222_12", "title": "Cervical Cancer -- Histopathology", "content": "Squamous cell carcinoma and adenocarcinoma are the most common histological subtypes of cervical cancer, with squamous cell carcinoma being vastly more frequent. Adenocarcinoma constitutes\u00a0approximately 5% of invasive cervical cancers worldwide, although this percentage is increasing in some countries. [15] Both subtypes result from precursor lesions, cervical intraepithelial neoplasia (CIN), or carcinoma in situ (CIS). Squamous CIS and adenocarcinoma in situ (AIS) are the most immediate precursors to invasive cervical cancer. Adenocarcinoma of the cervix should be carefully distinguished from endometrial adenocarcinoma with immunohistochemistry and HPV in situ hybridization. [16]", "contents": "Cervical Cancer -- Histopathology. Squamous cell carcinoma and adenocarcinoma are the most common histological subtypes of cervical cancer, with squamous cell carcinoma being vastly more frequent. Adenocarcinoma constitutes\u00a0approximately 5% of invasive cervical cancers worldwide, although this percentage is increasing in some countries. [15] Both subtypes result from precursor lesions, cervical intraepithelial neoplasia (CIN), or carcinoma in situ (CIS). Squamous CIS and adenocarcinoma in situ (AIS) are the most immediate precursors to invasive cervical cancer. Adenocarcinoma of the cervix should be carefully distinguished from endometrial adenocarcinoma with immunohistochemistry and HPV in situ hybridization. [16]"}
{"id": "article-19222_13", "title": "Cervical Cancer -- Histopathology", "content": "Most malignancies arise from the sqamocolumnar junction of the cervix. Microscopically, anastomosing irregular nests or single tumor cells with stromal inflammation or desmoplasia are present. Lymphovascular invasion (LVI) may\u00a0also be present. Grading is predicated on nuclear pleomorphism, nucleoli size, mitotic activity, and necrosis, and does not correlate with prognosis. [17]", "contents": "Cervical Cancer -- Histopathology. Most malignancies arise from the sqamocolumnar junction of the cervix. Microscopically, anastomosing irregular nests or single tumor cells with stromal inflammation or desmoplasia are present. Lymphovascular invasion (LVI) may\u00a0also be present. Grading is predicated on nuclear pleomorphism, nucleoli size, mitotic activity, and necrosis, and does not correlate with prognosis. [17]"}
{"id": "article-19222_14", "title": "Cervical Cancer -- History and Physical", "content": "Patients with cervical cancer are usually asymptomatic\u00a0during the early stages.\u00a0A complete medical history must include a sexual history, including the patient's age\u00a0at\u00a0first sexual encounter. Sexual history also includes questions about postcoital bleeding and pain during intercourse.\u00a0Questions about previous STIs, including HPV and HIV, the number of lifetime sexual partners, tobacco use, and prior vaccination against HPV are all vitally important. [18] Women should also be asked about menstrual patterns, abnormal bleeding, persistent vaginal discharges, irritations, and known cervical lesions. [19]", "contents": "Cervical Cancer -- History and Physical. Patients with cervical cancer are usually asymptomatic\u00a0during the early stages.\u00a0A complete medical history must include a sexual history, including the patient's age\u00a0at\u00a0first sexual encounter. Sexual history also includes questions about postcoital bleeding and pain during intercourse.\u00a0Questions about previous STIs, including HPV and HIV, the number of lifetime sexual partners, tobacco use, and prior vaccination against HPV are all vitally important. [18] Women should also be asked about menstrual patterns, abnormal bleeding, persistent vaginal discharges, irritations, and known cervical lesions. [19]"}
{"id": "article-19222_15", "title": "Cervical Cancer -- History and Physical", "content": "The physical exam must include a complete evaluation of the external and internal genitalia. Positive exam findings in women with cervical cancer might include a friable cervix, visible cervical lesions, erosions, masses, bleeding with the examination, and fixed adnexa. [20] Many patients will have no positive findings on physical examination. Screening by Pap and/or HPV testing is essential in the workup and diagnosis of patients with cervical cancer\u00a0and its precursor lesions.", "contents": "Cervical Cancer -- History and Physical. The physical exam must include a complete evaluation of the external and internal genitalia. Positive exam findings in women with cervical cancer might include a friable cervix, visible cervical lesions, erosions, masses, bleeding with the examination, and fixed adnexa. [20] Many patients will have no positive findings on physical examination. Screening by Pap and/or HPV testing is essential in the workup and diagnosis of patients with cervical cancer\u00a0and its precursor lesions."}
{"id": "article-19222_16", "title": "Cervical Cancer -- Evaluation", "content": "According to the United States Preventative\u00a0Services\u00a0Task Force (USPTF), Pap screening is recommended beginning at age 21; at\u00a0age 30, HPV testing starts in conjunction with Pap smear\u00a0cytology. Screening is recommended every\u00a03 years for women with continued negative screening results and those at low risk for cervical cancer. For women older than 30 years, cytology can be done every\u00a05 years with HPV testing. One Level A recommendation for women with low-risk status and consistently negative screenings is discontinuing cervical cytology and HPV testing at age 65. Women who have had a total abdominal hysterectomy, including removal of the cervix for benign disease, do not require\u00a0subsequent screening. [4]", "contents": "Cervical Cancer -- Evaluation. According to the United States Preventative\u00a0Services\u00a0Task Force (USPTF), Pap screening is recommended beginning at age 21; at\u00a0age 30, HPV testing starts in conjunction with Pap smear\u00a0cytology. Screening is recommended every\u00a03 years for women with continued negative screening results and those at low risk for cervical cancer. For women older than 30 years, cytology can be done every\u00a05 years with HPV testing. One Level A recommendation for women with low-risk status and consistently negative screenings is discontinuing cervical cytology and HPV testing at age 65. Women who have had a total abdominal hysterectomy, including removal of the cervix for benign disease, do not require\u00a0subsequent screening. [4]"}
{"id": "article-19222_17", "title": "Cervical Cancer -- Evaluation", "content": "Colposcopy is the diagnostic procedure of choice for evaluating abnormal cytology and/or persistent high-risk HPV infection. The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued guidance on procedural indications, and their recommended algorithms are considered standard of care.\u00a0Multiple colposcopic-guided biopsies and endocervical sampling\u00a0are often indicated, except during pregnancy. [21] Abnormal colposcopic findings may include acetowhite color change\u00a0with the application of acetic acid, rich vascularity, atypical vessels, mosaicism, and punctation (see Image. Invasive Cervical Cancer).", "contents": "Cervical Cancer -- Evaluation. Colposcopy is the diagnostic procedure of choice for evaluating abnormal cytology and/or persistent high-risk HPV infection. The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued guidance on procedural indications, and their recommended algorithms are considered standard of care.\u00a0Multiple colposcopic-guided biopsies and endocervical sampling\u00a0are often indicated, except during pregnancy. [21] Abnormal colposcopic findings may include acetowhite color change\u00a0with the application of acetic acid, rich vascularity, atypical vessels, mosaicism, and punctation (see Image. Invasive Cervical Cancer)."}
{"id": "article-19222_18", "title": "Cervical Cancer -- Evaluation", "content": "Patients diagnosed with invasive disease require a comprehensive staging workup. The International Federation of Gynecology and Obstetrics (FIGO) staging system\u00a0employs several methods to stage a patient's disease. Classically, staging was based on the local extent of the tumor, which could be determined with a combination of pelvic examination, cystoscopy, proctoscopy, chest x-ray, intravenous pyrography, and basic labs. More recently, advanced imaging modalities such as MRI and PET scans have been utilized for staging. A pelvic MRI is excellent\u00a0for detecting local tumor extension and can also be used for\u00a0monitoring tumor response. PET scans are more sensitive than CT scans for detecting nodal and visceral metastases. This is critical as nodal disease can significantly influence prognosis. [22]", "contents": "Cervical Cancer -- Evaluation. Patients diagnosed with invasive disease require a comprehensive staging workup. The International Federation of Gynecology and Obstetrics (FIGO) staging system\u00a0employs several methods to stage a patient's disease. Classically, staging was based on the local extent of the tumor, which could be determined with a combination of pelvic examination, cystoscopy, proctoscopy, chest x-ray, intravenous pyrography, and basic labs. More recently, advanced imaging modalities such as MRI and PET scans have been utilized for staging. A pelvic MRI is excellent\u00a0for detecting local tumor extension and can also be used for\u00a0monitoring tumor response. PET scans are more sensitive than CT scans for detecting nodal and visceral metastases. This is critical as nodal disease can significantly influence prognosis. [22]"}
{"id": "article-19222_19", "title": "Cervical Cancer -- Treatment / Management", "content": "Precancerous lesions are managed conservatively for women younger than 25 years. Most\u00a0positive findings in women younger than 25 years are low-risk cervical dysplasia and will\u00a0resolve spontaneously. Colposcopy evaluates persistent, abnormal cytology or lesions suspected to be\u00a0moderate or high risk. These are managed according to findings.", "contents": "Cervical Cancer -- Treatment / Management. Precancerous lesions are managed conservatively for women younger than 25 years. Most\u00a0positive findings in women younger than 25 years are low-risk cervical dysplasia and will\u00a0resolve spontaneously. Colposcopy evaluates persistent, abnormal cytology or lesions suspected to be\u00a0moderate or high risk. These are managed according to findings."}
{"id": "article-19222_20", "title": "Cervical Cancer -- Treatment / Management", "content": "Low-risk lesions may be\u00a0observed and reevaluated more frequently, and high-risk lesions are treated based on size, depth, and location. Cryotherapy or excision\u00a0is\u00a0performed to manage precancerous lesions limited in size and depth.\u00a0Conization, laser, or loop electrosurgical excision procedure (LEEP) are used to manage lesions that include the endocervical canal and are more extensive. LEEP may provide better visualization of the squamocolumnar junction and provide the benefit of less bleeding in the outpatient setting. [23]", "contents": "Cervical Cancer -- Treatment / Management. Low-risk lesions may be\u00a0observed and reevaluated more frequently, and high-risk lesions are treated based on size, depth, and location. Cryotherapy or excision\u00a0is\u00a0performed to manage precancerous lesions limited in size and depth.\u00a0Conization, laser, or loop electrosurgical excision procedure (LEEP) are used to manage lesions that include the endocervical canal and are more extensive. LEEP may provide better visualization of the squamocolumnar junction and provide the benefit of less bleeding in the outpatient setting. [23]"}
{"id": "article-19222_21", "title": "Cervical Cancer -- Treatment / Management", "content": "If invasive cancer is diagnosed, the next step in management is staging to determine further treatment. Staging is based on findings and results from\u00a0reported signs and symptoms, examination, tissue pathology, and imaging. Grading is based on the size and depth of the cancer and signs of spread to other organs. Treatment of early-stage disease is typically surgical resection, ranging from a conization to a modified radical hysterectomy. However, women with high-risk\u00a0pathology postresection may require adjuvant treatment with chemotherapy and radiation. Conization or trachelectomy may be an option for women with\u00a0early-stage disease who desire future fertility. For patients with more advanced disease, concurrent chemoradiation is the standard of care.", "contents": "Cervical Cancer -- Treatment / Management. If invasive cancer is diagnosed, the next step in management is staging to determine further treatment. Staging is based on findings and results from\u00a0reported signs and symptoms, examination, tissue pathology, and imaging. Grading is based on the size and depth of the cancer and signs of spread to other organs. Treatment of early-stage disease is typically surgical resection, ranging from a conization to a modified radical hysterectomy. However, women with high-risk\u00a0pathology postresection may require adjuvant treatment with chemotherapy and radiation. Conization or trachelectomy may be an option for women with\u00a0early-stage disease who desire future fertility. For patients with more advanced disease, concurrent chemoradiation is the standard of care."}
{"id": "article-19222_22", "title": "Cervical Cancer -- Differential Diagnosis", "content": "Evaluating visible cervical lesions for invasive cancer is essential. However, as discussed above, most cervical cancer is asymptomatic and will not present with an overt mass in the early stages. Other possible causes of cervical lesions and/or abnormal bleeding include STIs, cervical polyps or fibroids, and endometriosis. Diagnosis may require further evaluation\u00a0of symptoms and testing to determine whether the disease is cervical cancer.\u00a0A diagnostic biopsy is needed to finalize the diagnosis.", "contents": "Cervical Cancer -- Differential Diagnosis. Evaluating visible cervical lesions for invasive cancer is essential. However, as discussed above, most cervical cancer is asymptomatic and will not present with an overt mass in the early stages. Other possible causes of cervical lesions and/or abnormal bleeding include STIs, cervical polyps or fibroids, and endometriosis. Diagnosis may require further evaluation\u00a0of symptoms and testing to determine whether the disease is cervical cancer.\u00a0A diagnostic biopsy is needed to finalize the diagnosis."}
{"id": "article-19222_23", "title": "Cervical Cancer -- Differential Diagnosis", "content": "Other pathology-determined\u00a0conditions in the differential diagnosis include carcinosarcoma, epithelioid trophoblastic tumor, placental site nodule, immature squamous metaplasia, and metastatic disease from a noncervical primary tumor. Rarely, a routine Pap smear may identify metastatic cancer on the uterine cervix. [24]", "contents": "Cervical Cancer -- Differential Diagnosis. Other pathology-determined\u00a0conditions in the differential diagnosis include carcinosarcoma, epithelioid trophoblastic tumor, placental site nodule, immature squamous metaplasia, and metastatic disease from a noncervical primary tumor. Rarely, a routine Pap smear may identify metastatic cancer on the uterine cervix. [24]"}
{"id": "article-19222_24", "title": "Cervical Cancer -- Surgical Oncology", "content": "Surgical resection is offered to patients with early-stage disease confined to the cervix; it can range from relatively noninvasive\u00a0procedures such as cervical conization to more extensive operations such as radical hysterectomy.\u00a0Although surgery is the preferred treatment modality for early-stage cervical cancer, it is especially important in younger patients\u00a0for whom preservation of ovarian function and/or fertility is desired. Surgery is also indicated in select patients with recurrent disease.", "contents": "Cervical Cancer -- Surgical Oncology. Surgical resection is offered to patients with early-stage disease confined to the cervix; it can range from relatively noninvasive\u00a0procedures such as cervical conization to more extensive operations such as radical hysterectomy.\u00a0Although surgery is the preferred treatment modality for early-stage cervical cancer, it is especially important in younger patients\u00a0for whom preservation of ovarian function and/or fertility is desired. Surgery is also indicated in select patients with recurrent disease."}
{"id": "article-19222_25", "title": "Cervical Cancer -- Surgical Oncology -- Cervical conization", "content": "Cervical conization is typically indicated in patients with CIS or stage IA1 invasive cervical cancer. Using a scalpel or laser, a\u00a0cold knife cone (CKC) removes the cervical transformation zone and a portion of the cervix with at least a 3-mm margin. Pathologic evaluation of the margins and assessment of the presence or absence of lymphovascular invasion (LVI)\u00a0are critical. If a positive margin or LVI is present, reexcision or more invasive surgical treatment may be required.", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical conization. Cervical conization is typically indicated in patients with CIS or stage IA1 invasive cervical cancer. Using a scalpel or laser, a\u00a0cold knife cone (CKC) removes the cervical transformation zone and a portion of the cervix with at least a 3-mm margin. Pathologic evaluation of the margins and assessment of the presence or absence of lymphovascular invasion (LVI)\u00a0are critical. If a positive margin or LVI is present, reexcision or more invasive surgical treatment may be required."}
{"id": "article-19222_26", "title": "Cervical Cancer -- Surgical Oncology -- Cervical conization", "content": "If no LVI exists on the specimen, lymph node involvement is exceedingly rare, so nodal evaluation is unnecessary. Patients without any adverse pathologic findings may be observed. Recurrence rates are typically <10%, but patients must be followed closely with periodic colposcopy and cytology. Five-year survival rates exceed 95%. Complications include hemorrhage, infection, cervical incompetence, cervical stenosis, and infertility. The complication rate ranges from 2% to 12%. [25] [26]", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical conization. If no LVI exists on the specimen, lymph node involvement is exceedingly rare, so nodal evaluation is unnecessary. Patients without any adverse pathologic findings may be observed. Recurrence rates are typically <10%, but patients must be followed closely with periodic colposcopy and cytology. Five-year survival rates exceed 95%. Complications include hemorrhage, infection, cervical incompetence, cervical stenosis, and infertility. The complication rate ranges from 2% to 12%. [25] [26]"}
{"id": "article-19222_27", "title": "Cervical Cancer -- Surgical Oncology -- Radical trachelectomy", "content": "Patients\u00a0who are not candidates for conization due to adverse pathological features or more advanced disease but who desire future fertility are candidates for a radical trachelectomy. The procedure consists of removing most of the cervix, resecting the parametria, and mobilizing the ureters, bladder, and rectum. A 5-mm section of the cervix is preserved for the placement of a cerclage, allowing for future pregnancy. Due to the increased risk of nodal involvement, a lymph node evaluation with a sentinel node biopsy or pelvic lymphadenectomy typically accompanies a radical trachelectomy.", "contents": "Cervical Cancer -- Surgical Oncology -- Radical trachelectomy. Patients\u00a0who are not candidates for conization due to adverse pathological features or more advanced disease but who desire future fertility are candidates for a radical trachelectomy. The procedure consists of removing most of the cervix, resecting the parametria, and mobilizing the ureters, bladder, and rectum. A 5-mm section of the cervix is preserved for the placement of a cerclage, allowing for future pregnancy. Due to the increased risk of nodal involvement, a lymph node evaluation with a sentinel node biopsy or pelvic lymphadenectomy typically accompanies a radical trachelectomy."}
{"id": "article-19222_28", "title": "Cervical Cancer -- Surgical Oncology -- Radical trachelectomy", "content": "Adverse pathologic features such as positive margins, parametria involvement, lymph node involvement, or meeting Sedlis criteria would necessitate adjuvant treatment with radiotherapy with or without chemotherapy. A vaginal approach or laparotomy can be used, but there\u00a0are insufficient\u00a0data on minimally invasive techniques. The 5-year recurrence rate is approximately 5%, and the overall survival rate\u00a0is 97%.\u00a0The pregnancy rate postprocedure is 24%, with a live birth occurring in 75% of patients. [27] Complications include cervical suture problems, dysmenorrhea, isthmic stenosis, and vaginal discharge.", "contents": "Cervical Cancer -- Surgical Oncology -- Radical trachelectomy. Adverse pathologic features such as positive margins, parametria involvement, lymph node involvement, or meeting Sedlis criteria would necessitate adjuvant treatment with radiotherapy with or without chemotherapy. A vaginal approach or laparotomy can be used, but there\u00a0are insufficient\u00a0data on minimally invasive techniques. The 5-year recurrence rate is approximately 5%, and the overall survival rate\u00a0is 97%.\u00a0The pregnancy rate postprocedure is 24%, with a live birth occurring in 75% of patients. [27] Complications include cervical suture problems, dysmenorrhea, isthmic stenosis, and vaginal discharge."}
{"id": "article-19222_29", "title": "Cervical Cancer -- Surgical Oncology -- Extrafascial hysterectomy", "content": "Extrafascial hysterectomy, also known as a Type A radical hysterectomy, has a narrow range of clinical indications. [28] Typically, this surgery is offered to patients with stage IA1 disease who are not interested in future fertility; it involves the removal of the entire cervix and uterus. As ovarian removal is optional, ovarian function can be preserved. The parametria are not resected, and a vaginal approach or laparotomy may be utilized. Lymph node evaluations are not usually performed unless adverse pathologic features are discovered postoperatively. Patients with adverse pathologic features may require a complete parametrectomy or external beam radiotherapy with or without chemotherapy.", "contents": "Cervical Cancer -- Surgical Oncology -- Extrafascial hysterectomy. Extrafascial hysterectomy, also known as a Type A radical hysterectomy, has a narrow range of clinical indications. [28] Typically, this surgery is offered to patients with stage IA1 disease who are not interested in future fertility; it involves the removal of the entire cervix and uterus. As ovarian removal is optional, ovarian function can be preserved. The parametria are not resected, and a vaginal approach or laparotomy may be utilized. Lymph node evaluations are not usually performed unless adverse pathologic features are discovered postoperatively. Patients with adverse pathologic features may require a complete parametrectomy or external beam radiotherapy with or without chemotherapy."}
{"id": "article-19222_30", "title": "Cervical Cancer -- Surgical Oncology -- Radical hysterectomy", "content": "A radical hysterectomy may be considered in almost all early-stage cervical cancer cases when fertility preservation is not desired. The older Piver-Rutledge-Smith classification has been replaced by the Querleu\u2013Morrow system, which simplifies the classification process based solely on the extent of lateral parametria resection.\u00a0Four types of radical hysterectomy are described (Types A\u00a0through D). Type A includes a minimal parametrial resection. In contrast, Type D completely resects the paracervical region to the pelvic sidewall. The most commonly performed radical hysterectomies fall in the Type B and C categories, which differ in the transection of the paracervical region at the level of the ureters or internal iliac vessels, respectively. [29]", "contents": "Cervical Cancer -- Surgical Oncology -- Radical hysterectomy. A radical hysterectomy may be considered in almost all early-stage cervical cancer cases when fertility preservation is not desired. The older Piver-Rutledge-Smith classification has been replaced by the Querleu\u2013Morrow system, which simplifies the classification process based solely on the extent of lateral parametria resection.\u00a0Four types of radical hysterectomy are described (Types A\u00a0through D). Type A includes a minimal parametrial resection. In contrast, Type D completely resects the paracervical region to the pelvic sidewall. The most commonly performed radical hysterectomies fall in the Type B and C categories, which differ in the transection of the paracervical region at the level of the ureters or internal iliac vessels, respectively. [29]"}
{"id": "article-19222_31", "title": "Cervical Cancer -- Surgical Oncology -- Radical hysterectomy", "content": "Minimally invasive approaches have been shown to provide inferior oncologic outcomes compared\u00a0with more established open approaches in terms of disease-free survival (91% vs 97%) and overall survival (93% vs 99%), with most patients having stage IB1 disease. [30] Complications include bleeding, infection, venous thromboembolism, pulmonary embolus, small bowel obstruction, vesicovaginal fistula, hydronephrosis, ureteral injury, urinary stress incontinence, and lower extremity edema.", "contents": "Cervical Cancer -- Surgical Oncology -- Radical hysterectomy. Minimally invasive approaches have been shown to provide inferior oncologic outcomes compared\u00a0with more established open approaches in terms of disease-free survival (91% vs 97%) and overall survival (93% vs 99%), with most patients having stage IB1 disease. [30] Complications include bleeding, infection, venous thromboembolism, pulmonary embolus, small bowel obstruction, vesicovaginal fistula, hydronephrosis, ureteral injury, urinary stress incontinence, and lower extremity edema."}
{"id": "article-19222_32", "title": "Cervical Cancer -- Surgical Oncology -- Laparoscopic radical hysterectomy", "content": "Although this procedure offers a quicker recovery for the patient, it has been largely abandoned due to poor oncologic outcomes\u00a0and increased recurrence compared\u00a0with open surgery. The mechanism for this difference is unknown, but\u00a02 large independent studies have confirmed this finding. [31] [32] [33]", "contents": "Cervical Cancer -- Surgical Oncology -- Laparoscopic radical hysterectomy. Although this procedure offers a quicker recovery for the patient, it has been largely abandoned due to poor oncologic outcomes\u00a0and increased recurrence compared\u00a0with open surgery. The mechanism for this difference is unknown, but\u00a02 large independent studies have confirmed this finding. [31] [32] [33]"}
{"id": "article-19222_33", "title": "Cervical Cancer -- Surgical Oncology -- Lymph node evaluation", "content": "Detecting lymph node involvement is essential, as it yields important prognostic information and guides therapeutic decision-making. The risk of nodal involvement should guide the decision to evaluate the lymph nodes and is a function of the disease stage (see Table. Pelvic Nodal Risk\u00a0by Stage). Para-aortic (PA) nodal risk typically carries one-half the pelvic nodal risk by stage.\u00a0Although pelvic lymphadenectomies are considered the gold standard, sentinel node biopsies may also be pursued for select early stage I cervical cancer. Generally, sentinel node biopsies are safe and effective. They have been investigated in stage IA1\u00a0to stage IIA1 patients with a sensitivity of 92%, a negative predictive value of 98%, less lymphatic morbidity, and no differences in recurrence-free survival. [34] [35] The sentinel node biopsy approach continues to be investigated in large-scale international trials\u00a0called SENTICOL III (NCT03386734).", "contents": "Cervical Cancer -- Surgical Oncology -- Lymph node evaluation. Detecting lymph node involvement is essential, as it yields important prognostic information and guides therapeutic decision-making. The risk of nodal involvement should guide the decision to evaluate the lymph nodes and is a function of the disease stage (see Table. Pelvic Nodal Risk\u00a0by Stage). Para-aortic (PA) nodal risk typically carries one-half the pelvic nodal risk by stage.\u00a0Although pelvic lymphadenectomies are considered the gold standard, sentinel node biopsies may also be pursued for select early stage I cervical cancer. Generally, sentinel node biopsies are safe and effective. They have been investigated in stage IA1\u00a0to stage IIA1 patients with a sensitivity of 92%, a negative predictive value of 98%, less lymphatic morbidity, and no differences in recurrence-free survival. [34] [35] The sentinel node biopsy approach continues to be investigated in large-scale international trials\u00a0called SENTICOL III (NCT03386734)."}
{"id": "article-19222_34", "title": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration", "content": "Pelvic exenteration is the most radical surgical procedure for cervical cancer. Indications are confined to patients with central pelvic recurrence after radiotherapy or patients with stage IVA disease who cannot receive radiotherapy. Classically, a total pelvic exenteration includes the removal of the uterus, fallopian tubes, ovaries, vagina, bladder, urethra, and rectum. Reconstruction consists of an ileal conduit, or continent diversion, for the urinary system and an end colostomy for the GI system. Continent diversions include the Indiana and Miami pouch techniques. [36] [37]", "contents": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration. Pelvic exenteration is the most radical surgical procedure for cervical cancer. Indications are confined to patients with central pelvic recurrence after radiotherapy or patients with stage IVA disease who cannot receive radiotherapy. Classically, a total pelvic exenteration includes the removal of the uterus, fallopian tubes, ovaries, vagina, bladder, urethra, and rectum. Reconstruction consists of an ileal conduit, or continent diversion, for the urinary system and an end colostomy for the GI system. Continent diversions include the Indiana and Miami pouch techniques. [36] [37]"}
{"id": "article-19222_35", "title": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration", "content": "Total exenteration is generally performed for cervical cancer. Variations of this technique include anterior and posterior exenteration, which spare the rectum or the bladder, respectively. Exenteration can be further classified into supralevator and infralevator, depending on whether the urogenital diaphragm and levator muscles are removed. It is important to ensure that the central tumor can be completely resected and there is no metastatic disease. Minimally invasive pelvic exenteration has been described in the literature,\u00a0although further evaluation of this technique is warranted. [38] [39]", "contents": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration. Total exenteration is generally performed for cervical cancer. Variations of this technique include anterior and posterior exenteration, which spare the rectum or the bladder, respectively. Exenteration can be further classified into supralevator and infralevator, depending on whether the urogenital diaphragm and levator muscles are removed. It is important to ensure that the central tumor can be completely resected and there is no metastatic disease. Minimally invasive pelvic exenteration has been described in the literature,\u00a0although further evaluation of this technique is warranted. [38] [39]"}
{"id": "article-19222_36", "title": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration", "content": "A neovagina can be formed with a myocutaneuous flap or split-thickness skin graft with an omental J-flap. The posterior supralevator exenteration approach allows for the possibility of maintaining not only urinary function but fecal continence if a colonic anastomosis can be formed. The 5-year survival rate for patients treated with exenteration ranges from 40% to 50% in the recurrent setting. [40] At 3 and 5 years, local recurrence rates are 84% and 75%, respectively. [41] Survival is not impacted by the type of exenteration performed. [42] Mortality from the operation has fallen dramatically over the last 70 years to less than 5%, but surgical morbidity is over 50%. [41] Early complications include infection, abscess formation, thromboembolism, fistulas, urinary leakage, peritonitis, stoma necrosis, flap necrosis, and stump dehiscence. Late complications include stoma stenosis, incontinence, hydronephrosis, stone formation, chronic pain, and abdominal wall hernia.", "contents": "Cervical Cancer -- Surgical Oncology -- Pelvic exenteration. A neovagina can be formed with a myocutaneuous flap or split-thickness skin graft with an omental J-flap. The posterior supralevator exenteration approach allows for the possibility of maintaining not only urinary function but fecal continence if a colonic anastomosis can be formed. The 5-year survival rate for patients treated with exenteration ranges from 40% to 50% in the recurrent setting. [40] At 3 and 5 years, local recurrence rates are 84% and 75%, respectively. [41] Survival is not impacted by the type of exenteration performed. [42] Mortality from the operation has fallen dramatically over the last 70 years to less than 5%, but surgical morbidity is over 50%. [41] Early complications include infection, abscess formation, thromboembolism, fistulas, urinary leakage, peritonitis, stoma necrosis, flap necrosis, and stump dehiscence. Late complications include stoma stenosis, incontinence, hydronephrosis, stone formation, chronic pain, and abdominal wall hernia."}
{"id": "article-19222_37", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "Although cervical cancer is one of the most common malignancies diagnosed in pregnancy, it\u00a0poses\u00a0unique staging and treatment challenges in pregnant patients. A maternal-fetal medicine specialist should evaluate patients\u00a0to discuss fetal risks and potential pregnancy loss. Women must weigh the risk of delaying treatment until after delivery versus proceeding immediately with treatment.", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. Although cervical cancer is one of the most common malignancies diagnosed in pregnancy, it\u00a0poses\u00a0unique staging and treatment challenges in pregnant patients. A maternal-fetal medicine specialist should evaluate patients\u00a0to discuss fetal risks and potential pregnancy loss. Women must weigh the risk of delaying treatment until after delivery versus proceeding immediately with treatment."}
{"id": "article-19222_38", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "The determination of gestational age is crucial. Minimum fetal viability is approximately 24 weeks gestation, but there is a significant risk of neonatal death\u00a0or long-term disability in those who survive. Disability-free survival at 25 years increases substantially with\u00a0advancing gestational age, with 4% of infants born at 22 weeks versus 78% for those born at 28 weeks gestation.\u00a0In contrast, full-term infants have a disability-free survival of 97%. [43]", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. The determination of gestational age is crucial. Minimum fetal viability is approximately 24 weeks gestation, but there is a significant risk of neonatal death\u00a0or long-term disability in those who survive. Disability-free survival at 25 years increases substantially with\u00a0advancing gestational age, with 4% of infants born at 22 weeks versus 78% for those born at 28 weeks gestation.\u00a0In contrast, full-term infants have a disability-free survival of 97%. [43]"}
{"id": "article-19222_39", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "While the radiation delivered during a PET or CT scan remains far below the threshold for the development of\u00a0congenital malformations and pregnancy loss, ionizing radiation in imaging studies should be kept to a minimum in this population. [44] Other imaging modalities, such as ultrasound and MRI, are preferred when appropriate to determine local tumor extent and distant metastatic involvement. However, MRI and ultrasound have a low sensitivity for small nodal metastases. Consequently, more invasive staging techniques may need to be employed.", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. While the radiation delivered during a PET or CT scan remains far below the threshold for the development of\u00a0congenital malformations and pregnancy loss, ionizing radiation in imaging studies should be kept to a minimum in this population. [44] Other imaging modalities, such as ultrasound and MRI, are preferred when appropriate to determine local tumor extent and distant metastatic involvement. However, MRI and ultrasound have a low sensitivity for small nodal metastases. Consequently, more invasive staging techniques may need to be employed."}
{"id": "article-19222_40", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "In patients with a high risk of nodal metastasis, laparoscopic pelvic lymphadenectomy may be\u00a0performed to establish the disease stage. [45] The safety of this procedure has only been studied in limited case series, but it can be performed in any trimester\u00a0(although earlier\u00a0in the pregnancy\u00a0is preferred). These techniques may still be employed when advanced imaging is unavailable or contraindicated. In addition, the FIGO staging system continues to allow the use of proctosigmoidoscopy and cystoscopy for local staging of cervical cancer.", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. In patients with a high risk of nodal metastasis, laparoscopic pelvic lymphadenectomy may be\u00a0performed to establish the disease stage. [45] The safety of this procedure has only been studied in limited case series, but it can be performed in any trimester\u00a0(although earlier\u00a0in the pregnancy\u00a0is preferred). These techniques may still be employed when advanced imaging is unavailable or contraindicated. In addition, the FIGO staging system continues to allow the use of proctosigmoidoscopy and cystoscopy for local staging of cervical cancer."}
{"id": "article-19222_41", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "Treatment strategies must be individualized and discussed in a multidisciplinary fashion with medical oncologists, radiation oncologists, obstetrician/gynecologists, maternal-fetal medicine specialists, and gynecologic oncologists. Generally, patients with pregnancies at\u00a0gestational ages under 22 weeks and stage IA1 disease can be treated with conization, but this carries a 15% risk of significant bleeding and spontaneous abortion. Patients with pregnancies at gestational ages above 22 weeks may be able to delay treatment until after delivery if they have early-stage disease. Patients with more advanced disease (>IB1) may receive platinum-based neoadjuvant chemotherapy (cisplatin/paclitaxel) until delivery, followed by a cesarean\u00a0radical hysterectomy. Limited data suggest this is a safe regimen for both mother and fetus. [46] Small series indicate approximately a 75% tumor response rate, with 15% of patients experiencing a local recurrence. The risk of fetal toxicity with these regimens is unknown, but complications may include respiratory distress syndrome, malformations, and childhood malignancies. [46]  International guidelines for treatment and fetal preservation have been published. [47]", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. Treatment strategies must be individualized and discussed in a multidisciplinary fashion with medical oncologists, radiation oncologists, obstetrician/gynecologists, maternal-fetal medicine specialists, and gynecologic oncologists. Generally, patients with pregnancies at\u00a0gestational ages under 22 weeks and stage IA1 disease can be treated with conization, but this carries a 15% risk of significant bleeding and spontaneous abortion. Patients with pregnancies at gestational ages above 22 weeks may be able to delay treatment until after delivery if they have early-stage disease. Patients with more advanced disease (>IB1) may receive platinum-based neoadjuvant chemotherapy (cisplatin/paclitaxel) until delivery, followed by a cesarean\u00a0radical hysterectomy. Limited data suggest this is a safe regimen for both mother and fetus. [46] Small series indicate approximately a 75% tumor response rate, with 15% of patients experiencing a local recurrence. The risk of fetal toxicity with these regimens is unknown, but complications may include respiratory distress syndrome, malformations, and childhood malignancies. [46]  International guidelines for treatment and fetal preservation have been published. [47]"}
{"id": "article-19222_42", "title": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy", "content": "Immediate treatment is recommended for patients with documented lymph node metastasis, disease progression, or pregnancy termination. If the patient\u00a0opts to terminate the pregnancy before treatment, definitive treatment recommendations are\u00a0identical to those of a nonpregnant patient.", "contents": "Cervical Cancer -- Surgical Oncology -- Cervical Cancer in Pregnancy. Immediate treatment is recommended for patients with documented lymph node metastasis, disease progression, or pregnancy termination. If the patient\u00a0opts to terminate the pregnancy before treatment, definitive treatment recommendations are\u00a0identical to those of a nonpregnant patient."}
{"id": "article-19222_43", "title": "Cervical Cancer -- Radiation Oncology", "content": "Radiotherapy remains a crucial component in the treatment of cervical cancer. Randomized evidence from the 1990s and early 2000s has established radiotherapy in almost every facet of treatment; it may be utilized as a definitive or adjuvant treatment with or without platinum-based chemotherapy.", "contents": "Cervical Cancer -- Radiation Oncology. Radiotherapy remains a crucial component in the treatment of cervical cancer. Randomized evidence from the 1990s and early 2000s has established radiotherapy in almost every facet of treatment; it may be utilized as a definitive or adjuvant treatment with or without platinum-based chemotherapy."}
{"id": "article-19222_44", "title": "Cervical Cancer -- Radiation Oncology -- Early-stage cervical cancer", "content": "Radiotherapy may be utilized as the sole treatment modality in early-stage cervical cancer (stages IA1 to IIA1). External beam radiotherapy (EBRT) with a brachytherapy (BT) boost has less morbidity and equivalent 5- and 20-year overall survival rates (83% and 75%, respectively) compared\u00a0with radical hysterectomy. [48] [49] Some centers may perform an adjuvant hysterectomy for bulky tumors after chemoradiation therapy. However, most guidelines do not\u00a0recommend this due to significant complication rates. Recent data suggest that\u00a0survival rates after chemoradiation therapy and adjuvant hysterectomy are suboptimal. [50]", "contents": "Cervical Cancer -- Radiation Oncology -- Early-stage cervical cancer. Radiotherapy may be utilized as the sole treatment modality in early-stage cervical cancer (stages IA1 to IIA1). External beam radiotherapy (EBRT) with a brachytherapy (BT) boost has less morbidity and equivalent 5- and 20-year overall survival rates (83% and 75%, respectively) compared\u00a0with radical hysterectomy. [48] [49] Some centers may perform an adjuvant hysterectomy for bulky tumors after chemoradiation therapy. However, most guidelines do not\u00a0recommend this due to significant complication rates. Recent data suggest that\u00a0survival rates after chemoradiation therapy and adjuvant hysterectomy are suboptimal. [50]"}
{"id": "article-19222_45", "title": "Cervical Cancer -- Radiation Oncology -- Advanced cervical cancer", "content": "Locally aggressive and/or node-positive diseases\u00a0are typically treated with definitive concurrent platinum-based chemoradiotherapy followed by a\u00a0BT boost. The addition of chemotherapy to definitive radiotherapy has resulted in considerable improvement in overall survival compared\u00a0with radiotherapy alone, with an 8-year overall survival of 67% versus 41%.\u00a0Improvements in local recurrence and distant metastasis have also been noted. [51]", "contents": "Cervical Cancer -- Radiation Oncology -- Advanced cervical cancer. Locally aggressive and/or node-positive diseases\u00a0are typically treated with definitive concurrent platinum-based chemoradiotherapy followed by a\u00a0BT boost. The addition of chemotherapy to definitive radiotherapy has resulted in considerable improvement in overall survival compared\u00a0with radiotherapy alone, with an 8-year overall survival of 67% versus 41%.\u00a0Improvements in local recurrence and distant metastasis have also been noted. [51]"}
{"id": "article-19222_46", "title": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy", "content": "Radiotherapy with or without chemotherapy is recommended in the postoperative setting when specific pathologic findings are present. These findings are thought to represent an increased risk of recurrence.", "contents": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy. Radiotherapy with or without chemotherapy is recommended in the postoperative setting when specific pathologic findings are present. These findings are thought to represent an increased risk of recurrence."}
{"id": "article-19222_47", "title": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy", "content": "Conventionally, the Sedlis criteria guided the use of adjuvant radiotherapy without chemotherapy in postradical hysterectomy patients with at least 2 of the following\u00a03 features: tumor size greater than 4 cm, LVI, or more\u00a0than one-third stromal invasion. [52] These criteria were meant to identify patients with at least a 30% risk of relapse at 3 years. [53] Patients who met these criteria and were treated with pelvic radiotherapy were noted to have improved progression-free survival (78% vs 65%) and local recurrence (21% vs 14%). [52] More recently, there have been concerns that these criteria may overlook women who might benefit from adjuvant radiotherapy due to such a high threshold.\u00a0A nomogram incorporating the original Sedlis criteria and tumor histology has been developed to provide a more linear and continuous risk assessment rather than a simple threshold. [53]", "contents": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy. Conventionally, the Sedlis criteria guided the use of adjuvant radiotherapy without chemotherapy in postradical hysterectomy patients with at least 2 of the following\u00a03 features: tumor size greater than 4 cm, LVI, or more\u00a0than one-third stromal invasion. [52] These criteria were meant to identify patients with at least a 30% risk of relapse at 3 years. [53] Patients who met these criteria and were treated with pelvic radiotherapy were noted to have improved progression-free survival (78% vs 65%) and local recurrence (21% vs 14%). [52] More recently, there have been concerns that these criteria may overlook women who might benefit from adjuvant radiotherapy due to such a high threshold.\u00a0A nomogram incorporating the original Sedlis criteria and tumor histology has been developed to provide a more linear and continuous risk assessment rather than a simple threshold. [53]"}
{"id": "article-19222_48", "title": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy", "content": "Classically, the addition of chemotherapy to radiotherapy was guided by the Peters trial, which randomized patients with positive nodes, involved parametria, or positive surgical margins to radiotherapy alone or radiotherapy with concurrent platinum-based chemotherapy. The addition of chemotherapy resulted in a 10% improvement in overall survival at 4 years and almost a 20% improvement in progression-free survival over the same time frame. [54] More contemporary studies such as the STARS trial have sought to expand the use of chemotherapy in the adjuvant setting in patients meeting either the original Sedlis or Peters criteria. [55]", "contents": "Cervical Cancer -- Radiation Oncology -- Postoperative radiotherapy. Classically, the addition of chemotherapy to radiotherapy was guided by the Peters trial, which randomized patients with positive nodes, involved parametria, or positive surgical margins to radiotherapy alone or radiotherapy with concurrent platinum-based chemotherapy. The addition of chemotherapy resulted in a 10% improvement in overall survival at 4 years and almost a 20% improvement in progression-free survival over the same time frame. [54] More contemporary studies such as the STARS trial have sought to expand the use of chemotherapy in the adjuvant setting in patients meeting either the original Sedlis or Peters criteria. [55]"}
{"id": "article-19222_49", "title": "Cervical Cancer -- Radiation Oncology -- Delivery Techniques", "content": "The\u00a02 major delivery methods include ERBT, directed at the primary tumor and pelvic lymphatics, and BT,\u00a0in which a sealed radiation source is placed in close proximity to the tumor.", "contents": "Cervical Cancer -- Radiation Oncology -- Delivery Techniques. The\u00a02 major delivery methods include ERBT, directed at the primary tumor and pelvic lymphatics, and BT,\u00a0in which a sealed radiation source is placed in close proximity to the tumor."}
{"id": "article-19222_50", "title": "Cervical Cancer -- Radiation Oncology -- EBRT", "content": "EBRT\u00a0techniques include\u00a03-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiotherapy (IMRT). Intact cervical cancer patients\u2019 plans can be employed. A reduction in gastrointestinal and hematological\u00a0adverse effects has been documented with IMRT in both adjuvant and definitive settings. [56] [57]", "contents": "Cervical Cancer -- Radiation Oncology -- EBRT. EBRT\u00a0techniques include\u00a03-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiotherapy (IMRT). Intact cervical cancer patients\u2019 plans can be employed. A reduction in gastrointestinal and hematological\u00a0adverse effects has been documented with IMRT in both adjuvant and definitive settings. [56] [57]"}
{"id": "article-19222_51", "title": "Cervical Cancer -- Radiation Oncology -- ERBT simulation", "content": "Patients undergoing\u00a0EBRT can be placed in the supine position. Accounting for cervical motion is essential when using IMRT. This is accomplished by taking\u00a02 separate scans of patients, first with a full bladder followed by an empty bladder. Prone positioning may also be accomplished using a belly board; however, if there are large daily fraction shifts, IMRT may not be reproducible. Prone positioning may allow for a reduction in the small bowel dose when using IMRT. [58]", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT simulation. Patients undergoing\u00a0EBRT can be placed in the supine position. Accounting for cervical motion is essential when using IMRT. This is accomplished by taking\u00a02 separate scans of patients, first with a full bladder followed by an empty bladder. Prone positioning may also be accomplished using a belly board; however, if there are large daily fraction shifts, IMRT may not be reproducible. Prone positioning may allow for a reduction in the small bowel dose when using IMRT. [58]"}
{"id": "article-19222_52", "title": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation", "content": "Traditionally, pelvic fields were drawn on 2-D x-rays consisting of anterior-posterior (AP)/posterior-anterior\u00a0(PA) and opposed lateral fields comprising the 4-field box. The superior edge of the field was the bottom of L4 and inferiorly drawn to the bottom of the obturator foramen (or at least 3 cm below the lowest extent of disease). The lateral fields have the same superior/inferior borders, with the anterior border being the anterior pubic symphysis and the posterior border being the sacral hollow, including S2.", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation. Traditionally, pelvic fields were drawn on 2-D x-rays consisting of anterior-posterior (AP)/posterior-anterior\u00a0(PA) and opposed lateral fields comprising the 4-field box. The superior edge of the field was the bottom of L4 and inferiorly drawn to the bottom of the obturator foramen (or at least 3 cm below the lowest extent of disease). The lateral fields have the same superior/inferior borders, with the anterior border being the anterior pubic symphysis and the posterior border being the sacral hollow, including S2."}
{"id": "article-19222_53", "title": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation", "content": "More precise delineation of the gross disease and elective volumes can be accomplished in the era of CT-based planning, PET/CT fusions, and IMRT. A gross tumor volume (GTV) consists of gross disease seen on a CT, PET, and physical examination. An internal target volume (ITV) accounts for variation in bladder filling and can also be employed, but this requires the patient to have\u00a02 CT simulations (empty and full bladder). The clinical tumor volume (CTV) 1 expansion includes the entire cervix and uterus (if intact). Planning target volume (PTV) 1 on\u00a0primary disease is typically 1.5 cm. The CTV2 includes the parametrial tissue, paravaginal tissues, and at least one-half of the upper vagina. If there is vaginal involvement, consideration\u00a0should be given to covering the entire vagina. This PTV2 expansion should be 1.0 cm. The elective nodal volumes in the CTV3 should include obturator nodes, external iliac nodes, internal iliac nodes, and presacral nodes. If there is lower vaginal involvement, consideration should be given\u00a0to coverage of the inguinal nodes. PTV expansion on the elective nodes is typically 0.7 cm.", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation. More precise delineation of the gross disease and elective volumes can be accomplished in the era of CT-based planning, PET/CT fusions, and IMRT. A gross tumor volume (GTV) consists of gross disease seen on a CT, PET, and physical examination. An internal target volume (ITV) accounts for variation in bladder filling and can also be employed, but this requires the patient to have\u00a02 CT simulations (empty and full bladder). The clinical tumor volume (CTV) 1 expansion includes the entire cervix and uterus (if intact). Planning target volume (PTV) 1 on\u00a0primary disease is typically 1.5 cm. The CTV2 includes the parametrial tissue, paravaginal tissues, and at least one-half of the upper vagina. If there is vaginal involvement, consideration\u00a0should be given to covering the entire vagina. This PTV2 expansion should be 1.0 cm. The elective nodal volumes in the CTV3 should include obturator nodes, external iliac nodes, internal iliac nodes, and presacral nodes. If there is lower vaginal involvement, consideration should be given\u00a0to coverage of the inguinal nodes. PTV expansion on the elective nodes is typically 0.7 cm."}
{"id": "article-19222_54", "title": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation", "content": "Coverage of the\u00a0PA nodes may be necessary in cases\u00a0with evidence of disease in the nodal chain, or in cases in which the patient has a positive pelvic node and will not receive systemic therapy. In those instances, the superior boundary would become\u00a0the T12/L1 interspace, with the nodal strip ending at the top of the pelvic field L5/S1. [59] [60]", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT target delineation. Coverage of the\u00a0PA nodes may be necessary in cases\u00a0with evidence of disease in the nodal chain, or in cases in which the patient has a positive pelvic node and will not receive systemic therapy. In those instances, the superior boundary would become\u00a0the T12/L1 interspace, with the nodal strip ending at the top of the pelvic field L5/S1. [59] [60]"}
{"id": "article-19222_55", "title": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints", "content": "The standard whole pelvic dose is 45 to 50.4 Gy, specifically 1.8 to 2.0 Gy per fraction. Any gross nodal disease may be boosted to 60 Gy if possible, given that organs-at-risk (OAR) constraints are not exceeded.", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints. The standard whole pelvic dose is 45 to 50.4 Gy, specifically 1.8 to 2.0 Gy per fraction. Any gross nodal disease may be boosted to 60 Gy if possible, given that organs-at-risk (OAR) constraints are not exceeded."}
{"id": "article-19222_56", "title": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints", "content": "EBRT\u00a0has dramatically improved with the adoption of IMRT, reducing acute toxicity while maintaining oncologic outcomes. Typical\u00a0OAR include the rectum, bladder, bowel, femoral heads, and bone marrow. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC)  dose constraints can be an excellent guide. Typically, with EBRT, doses of 45 to 50 Gy alone will not lead to significant rates of acute bladder or bowel toxicity. [57]", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints. EBRT\u00a0has dramatically improved with the adoption of IMRT, reducing acute toxicity while maintaining oncologic outcomes. Typical\u00a0OAR include the rectum, bladder, bowel, femoral heads, and bone marrow. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC)  dose constraints can be an excellent guide. Typically, with EBRT, doses of 45 to 50 Gy alone will not lead to significant rates of acute bladder or bowel toxicity. [57]"}
{"id": "article-19222_57", "title": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints", "content": "If\u00a0BT is planned, minimizing these doses during the external beam phase of treatment will allow higher doses to be delivered during the boost phase of treatment. Bone marrow suppression resulting in grades 3 to 4 neutropenia has been demonstrably lower (8.6% vs 27.1%) with image-guided radiotherapy and IMRT. [56] The most common constraints are for bone marrow in the pelvis. [56] [57] [61]", "contents": "Cervical Cancer -- Radiation Oncology -- ERBT dosing and dose constraints. If\u00a0BT is planned, minimizing these doses during the external beam phase of treatment will allow higher doses to be delivered during the boost phase of treatment. Bone marrow suppression resulting in grades 3 to 4 neutropenia has been demonstrably lower (8.6% vs 27.1%) with image-guided radiotherapy and IMRT. [56] The most common constraints are for bone marrow in the pelvis. [56] [57] [61]"}
{"id": "article-19222_58", "title": "Cervical Cancer -- Radiation Oncology -- BT", "content": "BT\u00a0can be used alone in early-stage\u00a0cervical cancer or as a boost after EBRT in more advanced disease\u00a0(stages IB2\u00a0to IVA), as it allows for highly conformal dose delivery to the tumor while minimizing exposure to normal tissues. The dose delivery is controlled by adjusting the dwell times within the delivery device. High dose-rate (HDR)\u00a0BT (>12 Gy/hr) is the most commonly used technique; however, it requires a radioactive source, usually iridium-192.", "contents": "Cervical Cancer -- Radiation Oncology -- BT. BT\u00a0can be used alone in early-stage\u00a0cervical cancer or as a boost after EBRT in more advanced disease\u00a0(stages IB2\u00a0to IVA), as it allows for highly conformal dose delivery to the tumor while minimizing exposure to normal tissues. The dose delivery is controlled by adjusting the dwell times within the delivery device. High dose-rate (HDR)\u00a0BT (>12 Gy/hr) is the most commonly used technique; however, it requires a radioactive source, usually iridium-192."}
{"id": "article-19222_59", "title": "Cervical Cancer -- Radiation Oncology -- BT", "content": "Typically,\u00a0BT is started after the external beam portion of the treatment or interdigitated with EBRT in the last week of treatment. EBRT and\u00a0BT should not be administered on the same day. Total treatment time (EBRT and BT) should not exceed\u00a08\u00a0weeks. Excessive treatment times can result in a 1% per day decline in local control and overall survival.", "contents": "Cervical Cancer -- Radiation Oncology -- BT. Typically,\u00a0BT is started after the external beam portion of the treatment or interdigitated with EBRT in the last week of treatment. EBRT and\u00a0BT should not be administered on the same day. Total treatment time (EBRT and BT) should not exceed\u00a08\u00a0weeks. Excessive treatment times can result in a 1% per day decline in local control and overall survival."}
{"id": "article-19222_60", "title": "Cervical Cancer -- Radiation Oncology -- BT", "content": "Before undergoing BT, a review of the patient\u2019s history, physical exam, pathology, and imaging should be conducted. A complete blood count and metabolic panel should be obtained within a week of the procedure. Metabolic derangements should be investigated and corrected before the procedure. Patients with an absolute neutrophil count (ANC) less than 500 mm should not undergo the procedure until their count\u00a0has recovered. A review of medications, especially anticoagulants, should be completed, and a prothrombin time/international normalized ratio result should be obtained. Careful consideration should be given to holding anticoagulant medications before the procedure. Inpatients confined to bed should be given thromboprophylaxis and sequential compression devices. Bowel preparation should also be reviewed with the patient before the procedure.", "contents": "Cervical Cancer -- Radiation Oncology -- BT. Before undergoing BT, a review of the patient\u2019s history, physical exam, pathology, and imaging should be conducted. A complete blood count and metabolic panel should be obtained within a week of the procedure. Metabolic derangements should be investigated and corrected before the procedure. Patients with an absolute neutrophil count (ANC) less than 500 mm should not undergo the procedure until their count\u00a0has recovered. A review of medications, especially anticoagulants, should be completed, and a prothrombin time/international normalized ratio result should be obtained. Careful consideration should be given to holding anticoagulant medications before the procedure. Inpatients confined to bed should be given thromboprophylaxis and sequential compression devices. Bowel preparation should also be reviewed with the patient before the procedure."}
{"id": "article-19222_61", "title": "Cervical Cancer -- Radiation Oncology -- BT applicators", "content": "There are several applicators that may be used\u00a0in various clinical scenarios. The ring and tandem is the most common device for intact cervical cancer. The tandem is placed in the cervical canal while the ring is placed inside the vaginal fornices. Tandem and ovoids are utilized similarly but are preferred in patients with a barrel-shaped cervix. Interstitial applicators such as the Syed template can be used in patients with extensive parametria involvement, pelvic sidewall involvement, lower vaginal involvement, or vaginal cuff recurrence. Tandem and cylinder applicators can be used in cases of vaginal stenosis, inability to place a ring or ovoid, or lower vaginal involvement less than 5 mm\u00a0thick. Modifications to the tandem and ring or vaginal cylinder can also be made to accommodate interstitial needles. [62] [63]", "contents": "Cervical Cancer -- Radiation Oncology -- BT applicators. There are several applicators that may be used\u00a0in various clinical scenarios. The ring and tandem is the most common device for intact cervical cancer. The tandem is placed in the cervical canal while the ring is placed inside the vaginal fornices. Tandem and ovoids are utilized similarly but are preferred in patients with a barrel-shaped cervix. Interstitial applicators such as the Syed template can be used in patients with extensive parametria involvement, pelvic sidewall involvement, lower vaginal involvement, or vaginal cuff recurrence. Tandem and cylinder applicators can be used in cases of vaginal stenosis, inability to place a ring or ovoid, or lower vaginal involvement less than 5 mm\u00a0thick. Modifications to the tandem and ring or vaginal cylinder can also be made to accommodate interstitial needles. [62] [63]"}
{"id": "article-19222_62", "title": "Cervical Cancer -- Radiation Oncology -- BT applicators", "content": "Patient discomfort experienced during the procedure can lead to suboptimal placement of the applicator, longer procedure times, and distress for the patient. An anesthetic is typically required to help optimize patient comfort and procedure mechanics. The types of anesthesia administered vary but\u00a0may include general anesthesia, spinal anesthesia, epidural anesthesia, intravenous conscious sedation, and oral pain medication.", "contents": "Cervical Cancer -- Radiation Oncology -- BT applicators. Patient discomfort experienced during the procedure can lead to suboptimal placement of the applicator, longer procedure times, and distress for the patient. An anesthetic is typically required to help optimize patient comfort and procedure mechanics. The types of anesthesia administered vary but\u00a0may include general anesthesia, spinal anesthesia, epidural anesthesia, intravenous conscious sedation, and oral pain medication."}
{"id": "article-19222_63", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "The patient is placed in the dorsal lithotomy position in stirrups. After adequate sterile preparation of the area, a Foley catheter is inserted, and the balloon is inflated with dilute contrast to allow for detection\u00a0with CT scan. A speculum is inserted to visualize the cervix, and a uterine sound is used to determine the length of the cavity. This will aid in determining the length and angle of the tandem. A Smit sleeve is occasionally used to maintain the patency of the cervical os but, if not available, serial dilations may be required. Once this is complete, the tandem is inserted, followed by the ring or ovoid. Fiducial markers may also be placed during the procedure to outline the extent of the disease or the opening of the cervical os so it is visible on CT scan. These applicators can be locked so their relative positions do not change.", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. The patient is placed in the dorsal lithotomy position in stirrups. After adequate sterile preparation of the area, a Foley catheter is inserted, and the balloon is inflated with dilute contrast to allow for detection\u00a0with CT scan. A speculum is inserted to visualize the cervix, and a uterine sound is used to determine the length of the cavity. This will aid in determining the length and angle of the tandem. A Smit sleeve is occasionally used to maintain the patency of the cervical os but, if not available, serial dilations may be required. Once this is complete, the tandem is inserted, followed by the ring or ovoid. Fiducial markers may also be placed during the procedure to outline the extent of the disease or the opening of the cervical os so it is visible on CT scan. These applicators can be locked so their relative positions do not change."}
{"id": "article-19222_64", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "Displacement of the bladder and rectum is critical to reduce the excess dose and limit toxicity. The packing material can consist of gauze soaked in a radiopaque solution. Applicators fitted with inflatable balloons or separate rectal blades are also available. Anterior packing displaces the bladder, whereas posterior packing displaces the rectum. It is essential to ensure no packing is placed in front of the ring or ovoids, as this will significantly reduce the intended dose.", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. Displacement of the bladder and rectum is critical to reduce the excess dose and limit toxicity. The packing material can consist of gauze soaked in a radiopaque solution. Applicators fitted with inflatable balloons or separate rectal blades are also available. Anterior packing displaces the bladder, whereas posterior packing displaces the rectum. It is essential to ensure no packing is placed in front of the ring or ovoids, as this will significantly reduce the intended dose."}
{"id": "article-19222_65", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "Once complete, the patient will undergo a CT simulation for 3-D BT planning. Three-dimensional CT-based planning has been shown to have improved overall survival (65% vs 74%) and lower rates of grades 3\u00a0to 4 toxicity (23% vs 3%) compared\u00a0with 2-D planning. [64]  A 1- to 5-mm slice thickness is recommended. [62] [63] More recently, MRI-guided\u00a0BT has been incorporated into planning for improved tissue delineation, best seen on the T2-weighted fat-suppressed sequences (T2\u2013fast-spin echo) imaging. [65]", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. Once complete, the patient will undergo a CT simulation for 3-D BT planning. Three-dimensional CT-based planning has been shown to have improved overall survival (65% vs 74%) and lower rates of grades 3\u00a0to 4 toxicity (23% vs 3%) compared\u00a0with 2-D planning. [64]  A 1- to 5-mm slice thickness is recommended. [62] [63] More recently, MRI-guided\u00a0BT has been incorporated into planning for improved tissue delineation, best seen on the T2-weighted fat-suppressed sequences (T2\u2013fast-spin echo) imaging. [65]"}
{"id": "article-19222_66", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "Paraxial and para-coronal images should be obtained concerning the cervix-uteri and sagittal images. [66] These images can also allow for the assessment of chemoradiation\u00a0response.  Technically, low- and high-intensity magnetic field MRI machines can be used. Patients can be given glucagon before MRI to reduce bowel motion. A pelvic coil is recommended to increase the signal-to-noise ratio. Ideally, a 3-mm slice thickness should be obtained, which helps improve the detection of parametrial involvement, but a slice thickness of less than 5mm is acceptable. The disadvantages of this approach\u00a0are the increased costs, longer procedure times, and the need for strict compatibility of the materials utilized.", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. Paraxial and para-coronal images should be obtained concerning the cervix-uteri and sagittal images. [66] These images can also allow for the assessment of chemoradiation\u00a0response.  Technically, low- and high-intensity magnetic field MRI machines can be used. Patients can be given glucagon before MRI to reduce bowel motion. A pelvic coil is recommended to increase the signal-to-noise ratio. Ideally, a 3-mm slice thickness should be obtained, which helps improve the detection of parametrial involvement, but a slice thickness of less than 5mm is acceptable. The disadvantages of this approach\u00a0are the increased costs, longer procedure times, and the need for strict compatibility of the materials utilized."}
{"id": "article-19222_67", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "Proper applicator placement should be confirmed with plain radiography or more advanced imaging such as a CT scan or MRI. Adequate placement includes the tandem bisecting the ring/ovoids on AP and lateral imaging, the tandem being one-third to one-half the distance between the sacral promontory and the pubic symphysis, the tip of the tandem being below the sacral promontory, no packing located superior to the ring/ovoids, and no inferior displacement of the ring/ovoids relative to the flange.", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. Proper applicator placement should be confirmed with plain radiography or more advanced imaging such as a CT scan or MRI. Adequate placement includes the tandem bisecting the ring/ovoids on AP and lateral imaging, the tandem being one-third to one-half the distance between the sacral promontory and the pubic symphysis, the tip of the tandem being below the sacral promontory, no packing located superior to the ring/ovoids, and no inferior displacement of the ring/ovoids relative to the flange."}
{"id": "article-19222_68", "title": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix", "content": "With HDR BT, a remote afterloading technology allows a small iridium source attached to the end of a cable to be robotically driven through multiple channels, stopping at predetermined points (dwell positions) for varying lengths of time. [67] A Cochrane review\u00a0failed to show differences between HDR and\u00a0low dose-rate (LDR)\u00a0intracavitary brachytherapy (ICBT). Oncologic outcomes included overall survival, disease-free survival, and recurrence-free survival, as well as local control rate, recurrence, and metastasis. There was no difference in treatment-related complications. Regardless, this review recommends HDR ICBT for all clinical stages of cervix cancer due to the advantages of HDR ICBT, including accuracy of the source, applicator positioning, outpatient treatment, and patient convenience. [68]", "contents": "Cervical Cancer -- Radiation Oncology -- Placement of an intracavitary applicator for an intact cervix. With HDR BT, a remote afterloading technology allows a small iridium source attached to the end of a cable to be robotically driven through multiple channels, stopping at predetermined points (dwell positions) for varying lengths of time. [67] A Cochrane review\u00a0failed to show differences between HDR and\u00a0low dose-rate (LDR)\u00a0intracavitary brachytherapy (ICBT). Oncologic outcomes included overall survival, disease-free survival, and recurrence-free survival, as well as local control rate, recurrence, and metastasis. There was no difference in treatment-related complications. Regardless, this review recommends HDR ICBT for all clinical stages of cervix cancer due to the advantages of HDR ICBT, including accuracy of the source, applicator positioning, outpatient treatment, and patient convenience. [68]"}
{"id": "article-19222_69", "title": "Cervical Cancer -- Radiation Oncology -- BT target delineation", "content": "As part of 3-D\u2013based planning, contouring the targets is essential. The Groupe Europ\u00e9en de Curieth\u00e9rapie and the European Society for Radiotherapy and Oncology (GEC-ESTRO) have established standardized terminology regarding target delineation. [66] The high-risk clinical target volume (HR-CTV) consists of the entire cervix and all gross disease at the beginning of\u00a0BT treatment; the intermediate-risk clinical target volume (IR-CTV) incorporates the HR-CTV and gross disease before any treatment; and the low-risk clinical target volume (LR-CTV), which includes the IR-CTV as well as the entire uterus, upper vagina, entire parametria, and spaces between the bladder and rectum. [69] Normal OAR should be contoured, including the bladder, rectum, sigmoid colon, and vagina.", "contents": "Cervical Cancer -- Radiation Oncology -- BT target delineation. As part of 3-D\u2013based planning, contouring the targets is essential. The Groupe Europ\u00e9en de Curieth\u00e9rapie and the European Society for Radiotherapy and Oncology (GEC-ESTRO) have established standardized terminology regarding target delineation. [66] The high-risk clinical target volume (HR-CTV) consists of the entire cervix and all gross disease at the beginning of\u00a0BT treatment; the intermediate-risk clinical target volume (IR-CTV) incorporates the HR-CTV and gross disease before any treatment; and the low-risk clinical target volume (LR-CTV), which includes the IR-CTV as well as the entire uterus, upper vagina, entire parametria, and spaces between the bladder and rectum. [69] Normal OAR should be contoured, including the bladder, rectum, sigmoid colon, and vagina."}
{"id": "article-19222_70", "title": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints", "content": "Ensuring adequate dose to the target is critical and has been shown to lead to improved local control and survival. Dose and fractionation schemes may vary by institutional preference, but they must result in a total equivalent dose in 2\u00a0Gy fractions (EQD2) of 85 Gy or higher, assuming 45 Gy was initially delivered to the pelvis. There are several calculators\u00a0to determine\u00a0EQD2. One of these,\u00a0colloquially known as the \u201cVienna Spreadsheet,\u201d was used by the\u00a0Effects of a Multifaceted Intervention on Blood Pressure Actions in the Primary Care Environment (EMBRACE) trial group; it\u00a0provides EQD2 calculations to the target structures and OAR.\u00a0The most common dose fractionation schemes include 4\u00a0x 7 Gy, 5\u00a0x 6 Gy, and 6\u00a0x 5 Gy, with an EQD2 of approximately 90.1, 88.6, and 83.7 Gy, respectively.", "contents": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints. Ensuring adequate dose to the target is critical and has been shown to lead to improved local control and survival. Dose and fractionation schemes may vary by institutional preference, but they must result in a total equivalent dose in 2\u00a0Gy fractions (EQD2) of 85 Gy or higher, assuming 45 Gy was initially delivered to the pelvis. There are several calculators\u00a0to determine\u00a0EQD2. One of these,\u00a0colloquially known as the \u201cVienna Spreadsheet,\u201d was used by the\u00a0Effects of a Multifaceted Intervention on Blood Pressure Actions in the Primary Care Environment (EMBRACE) trial group; it\u00a0provides EQD2 calculations to the target structures and OAR.\u00a0The most common dose fractionation schemes include 4\u00a0x 7 Gy, 5\u00a0x 6 Gy, and 6\u00a0x 5 Gy, with an EQD2 of approximately 90.1, 88.6, and 83.7 Gy, respectively."}
{"id": "article-19222_71", "title": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints", "content": "For 3D-based planning, the critical dosimetric parameter is the D90 greater than or equal to 90%. The goal is for 90% of the HR-CTV to be covered by at least 90% of the prescription dose. The EQD2 should be calculated to ensure the total dose received is approximately 85 Gy or higher, although there are instances\u00a0in which it is acceptable for the EQD2 to be slightly lower. In\u00a0patients with a complete response before\u00a0BT or partial response with less than 4 cm in residual disease, an EQD2 above 80 Gy may be used, whereas for those patients with more than 4 cm residual disease, an EQD2\u00a0greater than 85 Gy is recommended. [62] [63]", "contents": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints. For 3D-based planning, the critical dosimetric parameter is the D90 greater than or equal to 90%. The goal is for 90% of the HR-CTV to be covered by at least 90% of the prescription dose. The EQD2 should be calculated to ensure the total dose received is approximately 85 Gy or higher, although there are instances\u00a0in which it is acceptable for the EQD2 to be slightly lower. In\u00a0patients with a complete response before\u00a0BT or partial response with less than 4 cm in residual disease, an EQD2 above 80 Gy may be used, whereas for those patients with more than 4 cm residual disease, an EQD2\u00a0greater than 85 Gy is recommended. [62] [63]"}
{"id": "article-19222_72", "title": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints", "content": "Despite the transition to 3D-based volumetric planning and the continued evolution of\u00a0BT treatment, 2-D dosimetric reporting systems persist and should be understood. Point A, where the uterine artery crosses the ureter, is located 2 cm up the tandem and 2 cm\u00a0lateral to the tandem and was originally part of the Manchester system. This point was traditionally where the prescription dose was prescribed, but more recently has become a starting point where dose coverage can be further manipulated in 3-D to ensure coverage of the HR-CTV. Point B, also part of the original Manchester system, is located 2 cm up the tandem and 5 cm from the patient\u2019s midline. This location represents the pelvic side wall lymphatics and typically receives\u00a0one-third of the prescription dose. It has fallen out of favor and is no longer reported. The isodose lines for typical tandem and ring/ovoid implant should appear pear-shaped. In addition, the International Commission on Radiation Units and Measurements (ICRU 38) specified a bladder and rectal point. The bladder point is located posterior to the Foley balloon that has been pulled down to the neck of the bladder. The rectal point is 5 mm posterior to the vaginal wall.", "contents": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints. Despite the transition to 3D-based volumetric planning and the continued evolution of\u00a0BT treatment, 2-D dosimetric reporting systems persist and should be understood. Point A, where the uterine artery crosses the ureter, is located 2 cm up the tandem and 2 cm\u00a0lateral to the tandem and was originally part of the Manchester system. This point was traditionally where the prescription dose was prescribed, but more recently has become a starting point where dose coverage can be further manipulated in 3-D to ensure coverage of the HR-CTV. Point B, also part of the original Manchester system, is located 2 cm up the tandem and 5 cm from the patient\u2019s midline. This location represents the pelvic side wall lymphatics and typically receives\u00a0one-third of the prescription dose. It has fallen out of favor and is no longer reported. The isodose lines for typical tandem and ring/ovoid implant should appear pear-shaped. In addition, the International Commission on Radiation Units and Measurements (ICRU 38) specified a bladder and rectal point. The bladder point is located posterior to the Foley balloon that has been pulled down to the neck of the bladder. The rectal point is 5 mm posterior to the vaginal wall."}
{"id": "article-19222_73", "title": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints", "content": "Doses to OAR must also be carefully documented. Again, it is the cumulative dose of EQD2 that is critical. The dosimetric parameter D2 cc, which represents the highest dose received by 2 ccs of tissue, is commonly used for evaluating a\u00a0BT plan. The American Brachytherapy Society (ABS) guidelines allow for the D2 cc of the bladder to receive 90 Gy or less EQD2, whereas the D2 cc of the rectum and sigmoid should be 75 Gy or less EQD2. However, recent data suggest that late rectal morbidity may be substantially lower even using a D2 cc\u00a0of 65 Gy or less. [70]", "contents": "Cervical Cancer -- Radiation Oncology -- BT dose and dose constraints. Doses to OAR must also be carefully documented. Again, it is the cumulative dose of EQD2 that is critical. The dosimetric parameter D2 cc, which represents the highest dose received by 2 ccs of tissue, is commonly used for evaluating a\u00a0BT plan. The American Brachytherapy Society (ABS) guidelines allow for the D2 cc of the bladder to receive 90 Gy or less EQD2, whereas the D2 cc of the rectum and sigmoid should be 75 Gy or less EQD2. However, recent data suggest that late rectal morbidity may be substantially lower even using a D2 cc\u00a0of 65 Gy or less. [70]"}
{"id": "article-19222_74", "title": "Cervical Cancer -- Radiation Oncology -- Radiation Therapy Complications", "content": "Long-term toxicity is a concern with any patient receiving radiation therapy. Bowel, rectal, and urinary complications are the most frequent. There does not appear to be a difference in the frequency or severity of complications with respect to age. The greatest risk of late sequelae typically occurs within 3 years of treatment.", "contents": "Cervical Cancer -- Radiation Oncology -- Radiation Therapy Complications. Long-term toxicity is a concern with any patient receiving radiation therapy. Bowel, rectal, and urinary complications are the most frequent. There does not appear to be a difference in the frequency or severity of complications with respect to age. The greatest risk of late sequelae typically occurs within 3 years of treatment."}
{"id": "article-19222_75", "title": "Cervical Cancer -- Radiation Oncology -- Proctitis", "content": "Radiation proctitis can result in tenesmus and intermittent bleeding with bowel movements. Postradiation proctitis typically occurs\u00a03 months after treatment at the earliest but may take years to develop. Treatments can include mesalamine or steroid-based suppositories to relieve pain and stop bleeding. Randomized trials have suggested that mesalamine may be slightly more efficacious than steroid-based suppositories. [71] Other treatments can include a 4% formaldehyde application to control rectal bleeding. In refractory cases, argon plasma laser coagulation may be performed on the offending vessels.", "contents": "Cervical Cancer -- Radiation Oncology -- Proctitis. Radiation proctitis can result in tenesmus and intermittent bleeding with bowel movements. Postradiation proctitis typically occurs\u00a03 months after treatment at the earliest but may take years to develop. Treatments can include mesalamine or steroid-based suppositories to relieve pain and stop bleeding. Randomized trials have suggested that mesalamine may be slightly more efficacious than steroid-based suppositories. [71] Other treatments can include a 4% formaldehyde application to control rectal bleeding. In refractory cases, argon plasma laser coagulation may be performed on the offending vessels."}
{"id": "article-19222_76", "title": "Cervical Cancer -- Radiation Oncology -- Cystitis", "content": "Radiation cystitis can lead to dysuria, urinary frequency, and, in some cases, hematuria. This complication can occur acutely within 2\u00a0to 3 weeks of starting radiotherapy and up to 3 years posttreatment.", "contents": "Cervical Cancer -- Radiation Oncology -- Cystitis. Radiation cystitis can lead to dysuria, urinary frequency, and, in some cases, hematuria. This complication can occur acutely within 2\u00a0to 3 weeks of starting radiotherapy and up to 3 years posttreatment."}
{"id": "article-19222_77", "title": "Cervical Cancer -- Radiation Oncology -- Cystitis", "content": "For acute cystitis, a urinary tract infection must be ruled out; therefore, a urinalysis is an appropriate first step in the diagnosis. A short course of\u00a0phenazopyridine can be prescribed for dysuria relief, although the urine color change may be alarming for some patients. Patients should be made aware of this change before starting the medication. Urinary frequency can be treated with anticholinergic drugs such as oxybutynin or mirabegron, although caution is advised in elderly patients.", "contents": "Cervical Cancer -- Radiation Oncology -- Cystitis. For acute cystitis, a urinary tract infection must be ruled out; therefore, a urinalysis is an appropriate first step in the diagnosis. A short course of\u00a0phenazopyridine can be prescribed for dysuria relief, although the urine color change may be alarming for some patients. Patients should be made aware of this change before starting the medication. Urinary frequency can be treated with anticholinergic drugs such as oxybutynin or mirabegron, although caution is advised in elderly patients."}
{"id": "article-19222_78", "title": "Cervical Cancer -- Radiation Oncology -- Cystitis", "content": "Chronic cystitis has an incidence of 5% to 10%. [72] These patients are more likely to experience hematuria in addition to frequency and dysuria. The severity can range from mild to severe and life-threatening. Mildly symptomatic patients may be managed conservatively. Any antiplatelet or anticoagulation medications the patient takes should be reviewed, and\u00a0the necessity questioned. A cystoscopy with clot evacuation and irrigation is necessary in more severe cases. During a cystoscopy, formalin instillation can be used to manage intractable hematuria. In refractory cases, hyperbaric oxygen therapy has been utilized and shown to relieve and control bleeding in 92% of patients; however, recurrences may occur. [73] Barotrauma is a risk associated with this procedure.", "contents": "Cervical Cancer -- Radiation Oncology -- Cystitis. Chronic cystitis has an incidence of 5% to 10%. [72] These patients are more likely to experience hematuria in addition to frequency and dysuria. The severity can range from mild to severe and life-threatening. Mildly symptomatic patients may be managed conservatively. Any antiplatelet or anticoagulation medications the patient takes should be reviewed, and\u00a0the necessity questioned. A cystoscopy with clot evacuation and irrigation is necessary in more severe cases. During a cystoscopy, formalin instillation can be used to manage intractable hematuria. In refractory cases, hyperbaric oxygen therapy has been utilized and shown to relieve and control bleeding in 92% of patients; however, recurrences may occur. [73] Barotrauma is a risk associated with this procedure."}
{"id": "article-19222_79", "title": "Cervical Cancer -- Radiation Oncology -- Secondary malignancy", "content": "Radiation-induced cancers tend to appear several decades after treatment. The overall risk of secondary malignancy is increased with pelvic radiotherapy compared to those treated with surgery alone. Women\u00a0younger than 50 years had a 40-year cumulative risk of 22% versus 16% for those older than 50 years. [74] Secondary cancers tend to be confined to the rectum, bladder, lungs, and genitals. Other retrospective studies have shown an increase in leukemia risk, which peaks around 5\u00a0to 10 years after treatment. [75] Limiting normal organ doses may help to reduce the risk.", "contents": "Cervical Cancer -- Radiation Oncology -- Secondary malignancy. Radiation-induced cancers tend to appear several decades after treatment. The overall risk of secondary malignancy is increased with pelvic radiotherapy compared to those treated with surgery alone. Women\u00a0younger than 50 years had a 40-year cumulative risk of 22% versus 16% for those older than 50 years. [74] Secondary cancers tend to be confined to the rectum, bladder, lungs, and genitals. Other retrospective studies have shown an increase in leukemia risk, which peaks around 5\u00a0to 10 years after treatment. [75] Limiting normal organ doses may help to reduce the risk."}
{"id": "article-19222_80", "title": "Cervical Cancer -- Radiation Oncology -- Ovarian failure", "content": "Radiation-induced ovarian failure typically occurs within 6 to 12 months after radiation. Minimum doses for ovarian failure are inversely related to age ranging from 20.3 Gy at birth to 14.3 Gy at the age of 30 years. [76] The doses used for cervical cancer can easily precipitate ovarian failure. Premenopausal patients have several options for preserving ovarian function, namely definitive surgery or ovarian transposition. Laparoscopic ovarian transposition allows the ovaries to be placed outside the radiation field, usually 3 cm away. This procedure is also useful for fertility preservation. The functional preservation rate is approximately 80%. Ovarian cryopreservation is another option. Exogenous hormonal supplementation with estrogen should be considered to prevent osteoporosis and osteopenia and to maintain libido.", "contents": "Cervical Cancer -- Radiation Oncology -- Ovarian failure. Radiation-induced ovarian failure typically occurs within 6 to 12 months after radiation. Minimum doses for ovarian failure are inversely related to age ranging from 20.3 Gy at birth to 14.3 Gy at the age of 30 years. [76] The doses used for cervical cancer can easily precipitate ovarian failure. Premenopausal patients have several options for preserving ovarian function, namely definitive surgery or ovarian transposition. Laparoscopic ovarian transposition allows the ovaries to be placed outside the radiation field, usually 3 cm away. This procedure is also useful for fertility preservation. The functional preservation rate is approximately 80%. Ovarian cryopreservation is another option. Exogenous hormonal supplementation with estrogen should be considered to prevent osteoporosis and osteopenia and to maintain libido."}
{"id": "article-19222_81", "title": "Cervical Cancer -- Radiation Oncology -- Vaginal stenosis", "content": "Vaginal stenosis and vaginal canal shortening can develop over months to years after treatment. Stenosis can make it difficult for intercourse and gynecological exams. Consistent use of a vaginal dilator is typically recommended; however, compliance is highly variable. Sexual dysfunction is quite common, ranging from a lack of desire for sexual activity to a lack of adequate vaginal lubrication.", "contents": "Cervical Cancer -- Radiation Oncology -- Vaginal stenosis. Vaginal stenosis and vaginal canal shortening can develop over months to years after treatment. Stenosis can make it difficult for intercourse and gynecological exams. Consistent use of a vaginal dilator is typically recommended; however, compliance is highly variable. Sexual dysfunction is quite common, ranging from a lack of desire for sexual activity to a lack of adequate vaginal lubrication."}
{"id": "article-19222_82", "title": "Cervical Cancer -- Radiation Oncology -- Bone fracture", "content": "Pelvic radiotherapy can increase the risk of pelvic fractures, with most fractures occurring at dose levels of 45 to 63 Gy. Bone health is another concern in patients\u00a0who undergo radiation to the pelvis. Approximately 10% of patients radiated for cervical cancer experience a pelvic fracture. The most common fracture site is the sacrum, most occurring within 2 years after treatment. Bone mineral density scans and appropriate intervention to maintain bone health may help to reduce this risk.", "contents": "Cervical Cancer -- Radiation Oncology -- Bone fracture. Pelvic radiotherapy can increase the risk of pelvic fractures, with most fractures occurring at dose levels of 45 to 63 Gy. Bone health is another concern in patients\u00a0who undergo radiation to the pelvis. Approximately 10% of patients radiated for cervical cancer experience a pelvic fracture. The most common fracture site is the sacrum, most occurring within 2 years after treatment. Bone mineral density scans and appropriate intervention to maintain bone health may help to reduce this risk."}
{"id": "article-19222_83", "title": "Cervical Cancer -- Radiation Oncology -- Uterine perforation", "content": "Uterine perforation is a complication related to\u00a0BT applicator insertion and results in excessive doses to normal tissues, poor target coverage, bleeding, and infection. Rates of perforation range from 2% to 18%. [77] [78] [79] Management is controversial, ranging from postponement of BT to allow for healing to outright abandonment of the procedure. However, treatment delays are known to adversely affect\u00a0patient outcomes. The risk of vascular and organ injury is low when a blunt instrument causes perforation. Stable patients without signs of infection may be discharged and observed. Prophylactic antibiotics may be prescribed. Signs of hemodynamic instability and infection warrant more aggressive approaches with IV fluids, antibiotics, and surgical exploration.", "contents": "Cervical Cancer -- Radiation Oncology -- Uterine perforation. Uterine perforation is a complication related to\u00a0BT applicator insertion and results in excessive doses to normal tissues, poor target coverage, bleeding, and infection. Rates of perforation range from 2% to 18%. [77] [78] [79] Management is controversial, ranging from postponement of BT to allow for healing to outright abandonment of the procedure. However, treatment delays are known to adversely affect\u00a0patient outcomes. The risk of vascular and organ injury is low when a blunt instrument causes perforation. Stable patients without signs of infection may be discharged and observed. Prophylactic antibiotics may be prescribed. Signs of hemodynamic instability and infection warrant more aggressive approaches with IV fluids, antibiotics, and surgical exploration."}
{"id": "article-19222_84", "title": "Cervical Cancer -- Medical Oncology -- Definitive Therapy", "content": "The Radiation Therapy Oncology\u00a0Group\u00a0(RTOG) trials established the utility of platinum-based chemotherapy regimens. Compared\u00a0with radiotherapy alone, there are consistent overall survival, disease-free survival, and local control advantages. [51] It is postulated that chemotherapy acts as a radiosensitizer. The most common agent used is weekly cisplatin. Single-agent platinum-based regimens have the best progression-free survival and overall survival compared to non-platinum-based regimens and a better toxicity profile than combinations of platinum-based regimens such as cisplatin/5-FU/hydroxyurea. [80] Carboplatin may also be used in patients who cannot tolerate cisplatin. Some practices continue to use a combination of cisplatin/5-FU. This regimen is delivered concurrently with radiotherapy.", "contents": "Cervical Cancer -- Medical Oncology -- Definitive Therapy. The Radiation Therapy Oncology\u00a0Group\u00a0(RTOG) trials established the utility of platinum-based chemotherapy regimens. Compared\u00a0with radiotherapy alone, there are consistent overall survival, disease-free survival, and local control advantages. [51] It is postulated that chemotherapy acts as a radiosensitizer. The most common agent used is weekly cisplatin. Single-agent platinum-based regimens have the best progression-free survival and overall survival compared to non-platinum-based regimens and a better toxicity profile than combinations of platinum-based regimens such as cisplatin/5-FU/hydroxyurea. [80] Carboplatin may also be used in patients who cannot tolerate cisplatin. Some practices continue to use a combination of cisplatin/5-FU. This regimen is delivered concurrently with radiotherapy."}
{"id": "article-19222_85", "title": "Cervical Cancer -- Medical Oncology -- Definitive Therapy", "content": "Adjuvant Therapy Chemoradiotherapy may be added after surgical resection should the patient have high-risk features. Overall survival and progression-free survival benefits have been demonstrated with the addition of chemotherapy to radiotherapy in certain high-risk postoperative patients. [54]", "contents": "Cervical Cancer -- Medical Oncology -- Definitive Therapy. Adjuvant Therapy Chemoradiotherapy may be added after surgical resection should the patient have high-risk features. Overall survival and progression-free survival benefits have been demonstrated with the addition of chemotherapy to radiotherapy in certain high-risk postoperative patients. [54]"}
{"id": "article-19222_86", "title": "Cervical Cancer -- Medical Oncology -- Definitive Therapy", "content": "The use of adjuvant chemotherapy after definitive chemoradiation continues to be investigated in clinical trials. The results have been mixed. Adding adjuvant carboplatin/taxol to chemoradiation for locally advanced cervical cancer resulted in higher rates of grades 3 to 5 toxicity and no difference in overall survival or progression-free survival. Another trial using concurrent and adjuvant cisplatin/gemcitabine demonstrated improved 3-year progression-free survival but markedly higher rates of grades 3 to 4 toxicity and hospitalizations. [81] RTOG 0724 is an ongoing trial investigating the use of adjuvant cisplatin/paclitaxel after definitive chemoradiation in high-risk postoperative patients (NCT00980954).", "contents": "Cervical Cancer -- Medical Oncology -- Definitive Therapy. The use of adjuvant chemotherapy after definitive chemoradiation continues to be investigated in clinical trials. The results have been mixed. Adding adjuvant carboplatin/taxol to chemoradiation for locally advanced cervical cancer resulted in higher rates of grades 3 to 5 toxicity and no difference in overall survival or progression-free survival. Another trial using concurrent and adjuvant cisplatin/gemcitabine demonstrated improved 3-year progression-free survival but markedly higher rates of grades 3 to 4 toxicity and hospitalizations. [81] RTOG 0724 is an ongoing trial investigating the use of adjuvant cisplatin/paclitaxel after definitive chemoradiation in high-risk postoperative patients (NCT00980954)."}
{"id": "article-19222_87", "title": "Cervical Cancer -- Medical Oncology -- Recurrence and Metastasis", "content": "In recurrent and metastatic disease settings, patients who are not candidates for exenterative surgery or radiotherapy may receive systemic therapy alone. Many patients have previously received single-agent cisplatin-based therapy; therefore, multidrug regimens are typically used. Cisplatin/paclitaxel has been shown to improve progression-free survival in patients with recurrent cervical cancer but yields no difference in median overall survival. [82] Although other drug combinations such as cisplatin/topotecan, cisplatin/gemcitabine, and cisplatin/vinorelbine are potential options, the Gynecologic Oncology Group (GOG) has suggested that these regimens are not superior to cisplatin/paclitaxel (protocol 204). [83] Incorporating biological agents such as vascular endothelial growth factor receptor antagonists\u00a0like bevacizumab into standard chemotherapeutic regimens has improved overall survival. [84] Immunotherapy with PD-1 inhibition has also been incorporated into chemotherapeutic regimens. Single-agent pembrolizumab has an objective response rate of 12% to 14% in patients with recurrent or metastatic cervical cancer. [85] Keynote-826, a randomized, double-blinded phase 3 study, demonstrated the addition of pembrolizumab to multidrug chemotherapy improved overall and progression-free survival. [86] Follow-up subgroup analysis confirmed this finding in a Japanese population. [87]", "contents": "Cervical Cancer -- Medical Oncology -- Recurrence and Metastasis. In recurrent and metastatic disease settings, patients who are not candidates for exenterative surgery or radiotherapy may receive systemic therapy alone. Many patients have previously received single-agent cisplatin-based therapy; therefore, multidrug regimens are typically used. Cisplatin/paclitaxel has been shown to improve progression-free survival in patients with recurrent cervical cancer but yields no difference in median overall survival. [82] Although other drug combinations such as cisplatin/topotecan, cisplatin/gemcitabine, and cisplatin/vinorelbine are potential options, the Gynecologic Oncology Group (GOG) has suggested that these regimens are not superior to cisplatin/paclitaxel (protocol 204). [83] Incorporating biological agents such as vascular endothelial growth factor receptor antagonists\u00a0like bevacizumab into standard chemotherapeutic regimens has improved overall survival. [84] Immunotherapy with PD-1 inhibition has also been incorporated into chemotherapeutic regimens. Single-agent pembrolizumab has an objective response rate of 12% to 14% in patients with recurrent or metastatic cervical cancer. [85] Keynote-826, a randomized, double-blinded phase 3 study, demonstrated the addition of pembrolizumab to multidrug chemotherapy improved overall and progression-free survival. [86] Follow-up subgroup analysis confirmed this finding in a Japanese population. [87]"}
{"id": "article-19222_88", "title": "Cervical Cancer -- Medical Oncology -- Complications", "content": "The most commonly used platinum-based drugs are cisplatin and carboplatin. Common\u00a0adverse effects include neutropenia, thrombocytopenia, anemia, febrile neutropenia, nephrotoxicity, neurotoxicity, and infection.\u00a0Although cisplatin is the drug of choice, carboplatin can be used in patients who may not tolerate cisplatin, particularly if they already have underlying renal disease.\u00a0 Carboplatin is thought to have lower efficacy than cisplatin; however, prospective data suggest noninferiority in effectiveness and a statistically significant lower incidence of febrile and nonfebrile neutropenia and creatinine elevation. [88]", "contents": "Cervical Cancer -- Medical Oncology -- Complications. The most commonly used platinum-based drugs are cisplatin and carboplatin. Common\u00a0adverse effects include neutropenia, thrombocytopenia, anemia, febrile neutropenia, nephrotoxicity, neurotoxicity, and infection.\u00a0Although cisplatin is the drug of choice, carboplatin can be used in patients who may not tolerate cisplatin, particularly if they already have underlying renal disease.\u00a0 Carboplatin is thought to have lower efficacy than cisplatin; however, prospective data suggest noninferiority in effectiveness and a statistically significant lower incidence of febrile and nonfebrile neutropenia and creatinine elevation. [88]"}
{"id": "article-19222_89", "title": "Cervical Cancer -- Medical Oncology -- Complications", "content": "Bevacizumab carries the risk of hypertension, hemorrhage, thromboembolic events, renal injury, and ovarian failure in premenopausal women. Pembrolizumab is known for precipitating autoimmune phenomena such as pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies.", "contents": "Cervical Cancer -- Medical Oncology -- Complications. Bevacizumab carries the risk of hypertension, hemorrhage, thromboembolic events, renal injury, and ovarian failure in premenopausal women. Pembrolizumab is known for precipitating autoimmune phenomena such as pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies."}
{"id": "article-19222_90", "title": "Cervical Cancer -- Staging", "content": "The International Federation of Gynecology and Obstetrics (FIGO) staging system was updated in 2018 and remains the dominant staging methodology. The\u00a08th edition of the American Joint Committee on Cancer (AJCC)\u00a0Staging Manual also has a\u00a0tumor-node-metastasis classification system\u00a0in which\u00a0the\u00a0tumor\u00a0stages correspond\u00a0with the FIGO stages; however, it is not regularly used.", "contents": "Cervical Cancer -- Staging. The International Federation of Gynecology and Obstetrics (FIGO) staging system was updated in 2018 and remains the dominant staging methodology. The\u00a08th edition of the American Joint Committee on Cancer (AJCC)\u00a0Staging Manual also has a\u00a0tumor-node-metastasis classification system\u00a0in which\u00a0the\u00a0tumor\u00a0stages correspond\u00a0with the FIGO stages; however, it is not regularly used."}
{"id": "article-19222_91", "title": "Cervical Cancer -- Staging -- FIGO Staging", "content": "Classically, FIGO staging would rely on clinical examination, cystoscopy, proctoscopy, hysteroscopy, urography, and plain film x-ray. These relatively basic tests were utilized\u00a0so developing countries with fewer healthcare resources could adequately stage patients. More recently, advanced imaging techniques such as MRI and PET scans have become part of the staging workup. MRI is preferred for establishing the\u00a0tumor\u00a0stage, given superior tissue delineation compared\u00a0with\u00a0CT scan with contrast. [89] [90]", "contents": "Cervical Cancer -- Staging -- FIGO Staging. Classically, FIGO staging would rely on clinical examination, cystoscopy, proctoscopy, hysteroscopy, urography, and plain film x-ray. These relatively basic tests were utilized\u00a0so developing countries with fewer healthcare resources could adequately stage patients. More recently, advanced imaging techniques such as MRI and PET scans have become part of the staging workup. MRI is preferred for establishing the\u00a0tumor\u00a0stage, given superior tissue delineation compared\u00a0with\u00a0CT scan with contrast. [89] [90]"}
{"id": "article-19222_92", "title": "Cervical Cancer -- Staging -- Stage I", "content": "The disease is strictly confined to the cervix, with the\u00a0A/B\u00a0designation indicating the depth of invasion (\u22645 or >5 mm).", "contents": "Cervical Cancer -- Staging -- Stage I. The disease is strictly confined to the cervix, with the\u00a0A/B\u00a0designation indicating the depth of invasion (\u22645 or >5 mm)."}
{"id": "article-19222_93", "title": "Cervical Cancer -- Staging -- Stage II", "content": "The disease invades beyond the uterus but has not extended into the lower vagina. This stage also has an\u00a0A/B\u00a0designation based on involvement of the parametria.", "contents": "Cervical Cancer -- Staging -- Stage II. The disease invades beyond the uterus but has not extended into the lower vagina. This stage also has an\u00a0A/B\u00a0designation based on involvement of the parametria."}
{"id": "article-19222_94", "title": "Cervical Cancer -- Staging -- Stage III", "content": "The disease has extended to the lower one-third of the vagina\u00a0(IIIA) or to the pelvic side wall and/or hydronephrosis (IIIB).", "contents": "Cervical Cancer -- Staging -- Stage III. The disease has extended to the lower one-third of the vagina\u00a0(IIIA) or to the pelvic side wall and/or hydronephrosis (IIIB)."}
{"id": "article-19222_95", "title": "Cervical Cancer -- Staging", "content": "Classically, nodal disease did not influence the FIGO staging system; however, it has been shown that nodal disease is one of the most important prognostic indicators for reduced 5-year overall survival. [91] As a result, new stages\u00a0(IIIC1\u00a0and\u00a0IIIC2)\u00a0were added to reflect the involvement of pelvic or\u00a0PA nodes, respectively.", "contents": "Cervical Cancer -- Staging. Classically, nodal disease did not influence the FIGO staging system; however, it has been shown that nodal disease is one of the most important prognostic indicators for reduced 5-year overall survival. [91] As a result, new stages\u00a0(IIIC1\u00a0and\u00a0IIIC2)\u00a0were added to reflect the involvement of pelvic or\u00a0PA nodes, respectively."}
{"id": "article-19222_96", "title": "Cervical Cancer -- Staging -- Stage IVA", "content": "The disease is\u00a0locally aggressive, involving adjacent organs such as the bladder or rectum.", "contents": "Cervical Cancer -- Staging -- Stage IVA. The disease is\u00a0locally aggressive, involving adjacent organs such as the bladder or rectum."}
{"id": "article-19222_97", "title": "Cervical Cancer -- Staging -- Stage IVB", "content": "The disease has spread to other solid distant organs; this stage can also be indicative of nonregional nodal disease.", "contents": "Cervical Cancer -- Staging -- Stage IVB. The disease has spread to other solid distant organs; this stage can also be indicative of nonregional nodal disease."}
{"id": "article-19222_98", "title": "Cervical Cancer -- Prognosis", "content": "Multiple factors contribute to\u00a0differences in patient outcomes.\u00a0Potential prognostic factors for cervical cancer patients include disease stage, number of retrieved lymph nodes, use of a uterine manipulator in laparoscopic treatment, age, race, ethnicity, general health before diagnosis, and access to evidence-based care. These prognostic factors highlight opportunities to\u00a0enhance care and\u00a0improve overall mortality.", "contents": "Cervical Cancer -- Prognosis. Multiple factors contribute to\u00a0differences in patient outcomes.\u00a0Potential prognostic factors for cervical cancer patients include disease stage, number of retrieved lymph nodes, use of a uterine manipulator in laparoscopic treatment, age, race, ethnicity, general health before diagnosis, and access to evidence-based care. These prognostic factors highlight opportunities to\u00a0enhance care and\u00a0improve overall mortality."}
{"id": "article-19222_99", "title": "Cervical Cancer -- Prognosis", "content": "When diagnosed\u00a0early,\u00a0the\u00a05-year relative survival rate for cervical cancer is approximately 92%. About 44% of cervical cancer patients are diagnosed at an early stage. Inconsistent screening is an independent risk factor for late diagnosis. [92] A higher stage at presentation decreases survival and increases the chance of recurrence. The 5-year relative survival rate\u00a0drops to\u00a060% when cervical cancer is diagnosed after it has spread locally or spread to regional lymph nodes. With distant metastasis at diagnosis,\u00a0the\u00a05-year relative survival rate is 19%.", "contents": "Cervical Cancer -- Prognosis. When diagnosed\u00a0early,\u00a0the\u00a05-year relative survival rate for cervical cancer is approximately 92%. About 44% of cervical cancer patients are diagnosed at an early stage. Inconsistent screening is an independent risk factor for late diagnosis. [92] A higher stage at presentation decreases survival and increases the chance of recurrence. The 5-year relative survival rate\u00a0drops to\u00a060% when cervical cancer is diagnosed after it has spread locally or spread to regional lymph nodes. With distant metastasis at diagnosis,\u00a0the\u00a05-year relative survival rate is 19%."}
{"id": "article-19222_100", "title": "Cervical Cancer -- Prognosis", "content": "Studies show certain surgical factors affect survival. It is believed that the number of retrieved lymph nodes corresponds to the thoroughness of surgical treatment. Research\u00a0indicates that a higher retrieved lymph node count has a statistically significant positive effect on progression-free survival. For women having laparoscopic surgery, the use\u00a0of a uterine manipulator is associated with\u00a0a better prognosis. [93]", "contents": "Cervical Cancer -- Prognosis. Studies show certain surgical factors affect survival. It is believed that the number of retrieved lymph nodes corresponds to the thoroughness of surgical treatment. Research\u00a0indicates that a higher retrieved lymph node count has a statistically significant positive effect on progression-free survival. For women having laparoscopic surgery, the use\u00a0of a uterine manipulator is associated with\u00a0a better prognosis. [93]"}
{"id": "article-19222_101", "title": "Cervical Cancer -- Prognosis", "content": "Survival rates also differ based on race. The 5-year relative survival rate is 67% for\u00a0women of all races.\u00a0Black women tend to have the highest mortality and lowest survival rate, with a 5-year relative survival rate of approximately 56%. [11] [94]", "contents": "Cervical Cancer -- Prognosis. Survival rates also differ based on race. The 5-year relative survival rate is 67% for\u00a0women of all races.\u00a0Black women tend to have the highest mortality and lowest survival rate, with a 5-year relative survival rate of approximately 56%. [11] [94]"}
{"id": "article-19222_102", "title": "Cervical Cancer -- Prognosis", "content": "Patient age at diagnosis also contributes to differences in prognosis and survival, independent of disease stage and histology. Older age\u00a0is associated with\u00a0lower survival rates. Patients\u00a0younger than 50 years,\u00a0aged 50\u00a0to 64 years, and 65 years and older have\u00a0relative 5-year survival rates of 77%, 61%, and 46%, respectively. Studies\u00a0indicate older women are a high-risk subset, often receive suboptimal treatment, and die more frequently.\u00a0Even with BT alone, older women with cervical cancer obtain significant survival benefits. [95]", "contents": "Cervical Cancer -- Prognosis. Patient age at diagnosis also contributes to differences in prognosis and survival, independent of disease stage and histology. Older age\u00a0is associated with\u00a0lower survival rates. Patients\u00a0younger than 50 years,\u00a0aged 50\u00a0to 64 years, and 65 years and older have\u00a0relative 5-year survival rates of 77%, 61%, and 46%, respectively. Studies\u00a0indicate older women are a high-risk subset, often receive suboptimal treatment, and die more frequently.\u00a0Even with BT alone, older women with cervical cancer obtain significant survival benefits. [95]"}
{"id": "article-19222_103", "title": "Cervical Cancer -- Complications", "content": "Complications of advanced disease and associated treatments are similar to other cancers. These late complications may include renal failure, hydronephrosis, pain, lymphedema, bleeding disorders, and fistulas (see Image. Secondary Lymphedema). [96]", "contents": "Cervical Cancer -- Complications. Complications of advanced disease and associated treatments are similar to other cancers. These late complications may include renal failure, hydronephrosis, pain, lymphedema, bleeding disorders, and fistulas (see Image. Secondary Lymphedema). [96]"}
{"id": "article-19222_104", "title": "Cervical Cancer -- Deterrence and Patient Education", "content": "Traditional and innovative patient education methods can increase overall awareness of cervical cancer and the need for prevention and early screening. [97] [98] Literature shows that healthcare professionals may not consistently recommend or discuss HPV vaccination with all target patients. Some women and parents of young daughters may also have reservations about vaccinations that\u00a0prevent them from being vaccinated. Additional medical education\u00a0for clinicians serving high-risk populations may increase awareness, prevention, and screening\u00a0of those patients at risk for the highest mortality. [99]", "contents": "Cervical Cancer -- Deterrence and Patient Education. Traditional and innovative patient education methods can increase overall awareness of cervical cancer and the need for prevention and early screening. [97] [98] Literature shows that healthcare professionals may not consistently recommend or discuss HPV vaccination with all target patients. Some women and parents of young daughters may also have reservations about vaccinations that\u00a0prevent them from being vaccinated. Additional medical education\u00a0for clinicians serving high-risk populations may increase awareness, prevention, and screening\u00a0of those patients at risk for the highest mortality. [99]"}
{"id": "article-19222_105", "title": "Cervical Cancer -- Deterrence and Patient Education", "content": "Although a patient may prefer\u00a0counseling directly\u00a0from the healthcare professional, additional community outreach efforts are necessary. Culturally sensitive information, appropriate language to reach lower health literacy populations, and targeted efforts to reach women not yet sexually active are needed to expand patient\u00a0awareness and education and to initiate screening beyond the clinical setting. [100] [101]", "contents": "Cervical Cancer -- Deterrence and Patient Education. Although a patient may prefer\u00a0counseling directly\u00a0from the healthcare professional, additional community outreach efforts are necessary. Culturally sensitive information, appropriate language to reach lower health literacy populations, and targeted efforts to reach women not yet sexually active are needed to expand patient\u00a0awareness and education and to initiate screening beyond the clinical setting. [100] [101]"}
{"id": "article-19222_106", "title": "Cervical Cancer -- Pearls and Other Issues", "content": "Primary prevention of cervical cancer involves HPV vaccination\u00a0to prevent cervical cancer.\u00a0The estimated effectiveness of HPV vaccination is 90%. [102] A\u00a0quadrivalent vaccine that prevents cervical cancer and genital warts caused by low-risk HPV types is widely available in the United States. The recommended and approved age for vaccination is 9 to 45 years for both females and males. Vaccination can significantly impact cervical cancer mortality in women in low-resource areas and those in high-risk racial and ethnic groups. A vaccine covering only\u00a0HPV-16 and -18 is no longer marketed in the United States. However, its use may continue in areas outside the United States.", "contents": "Cervical Cancer -- Pearls and Other Issues. Primary prevention of cervical cancer involves HPV vaccination\u00a0to prevent cervical cancer.\u00a0The estimated effectiveness of HPV vaccination is 90%. [102] A\u00a0quadrivalent vaccine that prevents cervical cancer and genital warts caused by low-risk HPV types is widely available in the United States. The recommended and approved age for vaccination is 9 to 45 years for both females and males. Vaccination can significantly impact cervical cancer mortality in women in low-resource areas and those in high-risk racial and ethnic groups. A vaccine covering only\u00a0HPV-16 and -18 is no longer marketed in the United States. However, its use may continue in areas outside the United States."}
{"id": "article-19222_107", "title": "Cervical Cancer -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional team can provide public health education and multidisciplinary care to improve cervical cancer awareness, prevention, screening, and management. [103] [104] [105] Primary care\u00a0clinicians performing cervical cancer screening, colposcopies, and LEEP procedures, must have ongoing dialogues with gynecologists about findings of suspicious cervical lesions, management, and treatment.\u00a0Appropriate protocols and guidelines across healthcare systems can improve outcomes\u00a0by\u00a0optimizing treatment and follow-up. Developing a culturally sensitive system directed at increasing patient-centered education will require the input of diverse healthcare professionals and staff with\u00a0multilingual skills and cross-cultural competency.", "contents": "Cervical Cancer -- Enhancing Healthcare Team Outcomes. The interprofessional team can provide public health education and multidisciplinary care to improve cervical cancer awareness, prevention, screening, and management. [103] [104] [105] Primary care\u00a0clinicians performing cervical cancer screening, colposcopies, and LEEP procedures, must have ongoing dialogues with gynecologists about findings of suspicious cervical lesions, management, and treatment.\u00a0Appropriate protocols and guidelines across healthcare systems can improve outcomes\u00a0by\u00a0optimizing treatment and follow-up. Developing a culturally sensitive system directed at increasing patient-centered education will require the input of diverse healthcare professionals and staff with\u00a0multilingual skills and cross-cultural competency."}
{"id": "article-19222_108", "title": "Cervical Cancer -- Enhancing Healthcare Team Outcomes", "content": "The interprofessional team can optimize the treatment of patients with cervical cancer through communication and coordination of care. Primary care physicians, gynecologists, gynecologic oncologists, radiation oncologists, and\u00a0advanced practice practitioners provide diagnoses and care plans. Specialty care, ambulatory care, and oncology nurses should work with the team to coordinate care,\u00a0support patient education, and provide feedback to the rest of the team. Pharmacists should evaluate vaccinations and medications, recognize drug-to-drug interactions, provide patient education, and monitor compliance. Together, the team can improve outcomes for patients with cervical cancer.", "contents": "Cervical Cancer -- Enhancing Healthcare Team Outcomes. The interprofessional team can optimize the treatment of patients with cervical cancer through communication and coordination of care. Primary care physicians, gynecologists, gynecologic oncologists, radiation oncologists, and\u00a0advanced practice practitioners provide diagnoses and care plans. Specialty care, ambulatory care, and oncology nurses should work with the team to coordinate care,\u00a0support patient education, and provide feedback to the rest of the team. Pharmacists should evaluate vaccinations and medications, recognize drug-to-drug interactions, provide patient education, and monitor compliance. Together, the team can improve outcomes for patients with cervical cancer."}
{"id": "article-19222_109", "title": "Cervical Cancer -- Review Questions", "content": "Access free multiple choice questions on this topic. Access free CME on this topic. Comment on this article.", "contents": "Cervical Cancer -- Review Questions. Access free multiple choice questions on this topic. Access free CME on this topic. Comment on this article."}